Myocarditis and Pericarditis following COVID-19 Vaccination: Rapid Systematic Review of Incidence, Risk Factors, and Clinical Course

Authors: Jennifer Pillay, MSc, Liza Bialy, MSc, Lindsay Gaudet, MSc, Aireen Wingert, MSc, Andrew S. Mackie, MD, SM, FRCPC, D. Ian Paterson, MD, FRCPC, Lisa Hartling, PhD

Appendices

Appendix 1. Search strategies

Ovid Multifile

Database: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations and Daily <1946 to October 05, 2021>, Embase <1974 to 2021 October 05> Search Strategy:

- 1 COVID-19 Vaccines/ [COVID VACCINES PT 1] (11038)
- 2 COVID-19/ (152175)
- 3 SARS-CoV-2/(101136)
- 4 Coronavirus/ (13257)
- 5 Betacoronavirus/ (40795)
- 6 Coronavirus Infections/ (56640)
- 7 (COVID-19 or COVID19).tw,kf. (324030)
- 8 ((coronavirus* or corona virus*) and (hubei or wuhan or beijing or shanghai)).tw,kf. (10884)
- 9 (wuhan adj5 virus*).tw,kf. (569)
- 10 (2019-nCoV or 19nCoV or 2019nCoV).tw,kf. (3694)
- 11 (nCoV or n-CoV or "CoV 2" or CoV2).tw,kf. (124619)

12 (SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or SARS2 or SARS-2 or severe acute respiratory syndrome coronavirus 2).tw,kf. (126706)

13 (2019-novel CoV or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus* or ((novel or new or nouveau) adj2 (CoV or nCoV or covid or coronavirus* or corona virus or Pandemi*2)) or (coronavirus* and pneumonia)).tw,kf. (41877)

- 14 (novel coronavirus* or novel corona virus* or novel CoV).tw,kf. (20703)
- 15 ((coronavirus* or corona virus*) adj2 "2019").tw,kf. (71612)
- 16 ((coronavirus* or corona virus*) adj2"19").tw,kf. (11500)
- 17 ("coronavirus 2" or "corona virus 2").tw,kf. (38199)
- 18 (OC43 or NL63 or 229E or HKU1 or HCoV* or Sars-coronavirus*).tw,kf. (8144)
- 19 COVID-19.rx,px,ox. or severe acute respiratory syndrome coronavirus 2.os. (9120)
- 20 (coronavirus* or corona virus*).ti. (48015)
- 21 COVID.ti. (254131)
- 22 ("B.1.1.7" or "B.1.351" or "B.1.617" or "B.1.427" or "B.1.429").tw,kf,rx,px,ox. (1406)
- 23 ("P.1" and (Brazil* or variant?)).tw,kf,rx,px,ox. (3731)
- 24 (((alpha or beta or delta or eta or gamma or iota or kappa or lambda) adj3 variant?) and (coronavirus* or corona virus* or covid*)).tw,kf. (459)
- 25 or/2-24 [COVID-19] (397323)
- 26 exp Vaccination/ (278048)
- 27 ((COVID or COVID-19 or COVID19) adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kf. (15689)
- 28 ((coronavirus* or corona virus*) adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kf. (3065)

29 ((2019-nCoV or nCoV or n-CoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or SARS2 or SARS-2 or OC43 or NL63 or 229E or HKU1 or HCoV*) adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kf. (8201)

30 (BNT162 or BNT162-01 or BNT162a1 or BNT162b1 or BNT162b2 or BNT162c2 or N38TVC63NU).tw,kf. (1584)

- 31 (AZD1222 or ChAdOx1 or Covishield\$2 or B5S3K2V0G8).tw,kf. (967)
- 32 (mRNA-1273 or EPK39PL4R4).tw,kf. (596)
- 33 (mRNA adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kf. (4901)
- 34 (messenger RNA adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kf. (462)
- 35 LV-SMENP-DC.tw,kf. (6)
- 36 (Ad5-nCoV or hAdOx1 nCoV-19).tw,kf. (39)
- 37 ("Ad26.COV2.S" or Ad26COVS1 or JNJ 78436735 or JNJ-78436735 or JT2NS6183B).tw,kf. (195)
- 38 (Janssen adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kf. (142)
- 39 ČX-024414.ťw, kf. (2)
- 40 (Moderna adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kf. (470)
- 41 Spikevax\$2.tw,kf. (11)
- 42 ((Pfizer or Pfizer-BioNTech) adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kf. (1249)
- 43 (Comirnaty\$2 or Tozinameran\$2).tw,kf. (202)
- 44 ((AstraZeneca or AZ or Oxford) adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kf. (731)
- 45 Vaxzevria\$2.tw,kf. (119)
- 46 or/26-45 [VACCINES] (295717)
- 47 25 and 46 [COVID-VACCINES PT 2] (26788)
- 48 1 or 47 [COVID-VACCINES PTS 1-2] (28932)
- 49 COVID-19 Vaccines/ae [adverse events] (933)
- 50 Viral Vaccines/ae [adverse events] (2911)
- 51 Adverse Drug Reaction Reporting Systems/ (10804)

52 ((immunis* or immuniz* or inoculat* or vaccin*) adj10 (adverse* or ADE or ADEs or ADR or ADRs or complication* or harm* or safe or safety or side effect? or undesirable effect? or undesirable consequence? or undesirable outcome? or unintended effect? or unintended consequence? or unintended outcome?)).tw,kf. (76675)

53 ((post-vaccin* or post-immuni#ation* or post-innoculat* or after vaccin* or after immuni#ation* or after innoculat* or (following adj3 vaccin*) or (following adj3 immuni#ation*) or (following adj3 innoculat*)) adj10 (adverse* or ADE or ADEs or ADR or ADRs or complication* or harm* or safe or safety or side effect? or undesirable effect? or undesirable consequence? or undesirable outcome? or unintended effect? or unintended consequence? or unintended outcome?)).tw,kf. (6413)

54 ((post-vaccin* or post-immuni#ation* or post-innoculat* or after vaccin* or after immuni#ation* or after innoculat* or (following adj3 vaccin*) or (following adj3 immuni#ation*) or (following adj3 innoculat*)) adj10 (complication? or consequenc* or effect? or event? or harm* or outcome?)).tw,kf. (7716)

- 55 (vaccine-associated or vaccine-induced or vaccine-related).tw,kf. (20509)
- 56 (immuni#ation-associated or immuni#ation-induced or immuni#ation-related).tw,kf. (1855)
- 57 ((data or vaccin*) adj3 (monitor* or surveillance*)).tw,kf. (73396)
- 58 Pharmacovigilance/ (5248)
- 59 (pharmacovigilan* or pharmaco-vigilan*).tw,kf. (18894)
- 60 (Canada Vigilance or Eudravigilance* or FAERS or VAERS).tw,kf. (2780)
- 61 Product Surveillance, Postmarketing/ (19287)
- 62 ((postmarket* or post-market*) adj3 surveillance*).tw,kf. (9589)
- 63 "Clinical Trial, Phase IV".pt. (2193)
- 64 ((Phase 4 or Phase IV) adj3 (evaluation? or study or studies or trial?)).tw,kf. (4910)
- 65 Cardiomyopathies/ (54974)
- 66 (cardiomyopath* or cardio-myopath* or myocardiopath* or myo-cardiopath*).tw,kf. (209222)

- 67 Myocarditis/ (42633)
- 68 myocarditis.tw,kf. (41845)
- 69 ((myocard* or myo-card) adj3 inflam*).tw,kf. (10214)
- 70 carditis.tw,kf. (4148)
- 71 exp Pericarditis/ (31618)
- 72 pericarditis.tw,kf. (27519)
- 73 ((pericard* or peri-card*) adj3 inflam*).tw,kf. (1118)
- 74 epicarditis.tw,kf. (249)
- 75 ((epicard* or epi-card*) adj3 inflam*).tw,kf. (260)
- 76 (myopericarditis or myo-pericarditis).tw,kf. (1763)
- 77 ((myopericard* or myo-pericard*) adj inflam*).tw,kf. (13)
- 78 (pleuropericarditis or pleuro-pericarditis).tw,kf. (412)
- 79 ((pleuropericard* or pleuropericard*) adj3 inflam*).tw,kf. (12)
- 80 or/49-79 [AEs, MYOCARDITIS, PERICARDITIS] (535683)
- 48 and 80 [COVID-VACCINES AEs, MYOCARDITIS, PERICARDITIS] (6406)
- 82 exp Animals/ not Humans/ (16924647)
- 83 81 not 82 [ANIMAL-ONLY REMOVED] (4653)
- 84 (comment or editorial or news or newspaper article or (letter not (letter and randomized controlled trial))).pt. (4104337)
- 85 83 not 84 [OPINION PIECES REMOVED] (4141)
- 86 limit 85 to yr="2020-current" (4046)
- 87 (202010* or 202011* or 202012* or 2021*).dt. (1600708)
- 88 86 and 87 [RECORDS SINCE 1 OCT 2020] (2589)
- 89 88 use ppez [MEDLINE RECORDS] (2589)
- 90 SARS-CoV-2 vaccine/ [COVID VACCINES PT 1] (11038)
- 91 coronavirus disease 2019/ (261337)
- 92 severe acute respiratory syndrome coronavirus 2/ (130655)
- 93 Coronavirinae/ (5218)
- 94 Betacoronavirus/ (40795)
- 95 coronavirus infection/(57662)
- 96 (COVID-19 or COVID19).tw,kw,kf. (324030)
- 97 ((coronavirus* or corona virus*) and (hubei or wuhan or beijing or shanghai)).tw,kw,kf. (10884)
- 98 (wuhan adj5 virus*).tw,kw,kf. (584)
- 99 (2019-nCoV or 19nCoV or 2019nCoV).tw,kw,kf. (3694)
- 100 (nCoV or n-CoV or "CoV 2" or CoV2).tw,kw,kf. (124619)
- 101 (SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or SARS2 or SARS-2 or severe acute respiratory syndrome coronavirus 2).tw,kw,kf. (126706)
- 102 (2019-novel CoV or Sars-coronavirus2 or Sars-coronavirus-2 or SARS-like coronavirus* or ((novel or new or nouveau) adj2 (CoV or nCoV or covid or coronavirus* or corona virus or Pandemi*2)) or (coronavirus* and pneumonia)).tw,kw,kf. (41884)
- 103 (novel coronavirus* or novel corona virus* or novel CoV).tw,kw,kf. (20703)
- 104 ((coronavirus* or corona virus*) adj2 "2019").tw,kw,kf. (71614)
- 105 ((coronavirus* or corona virus*) adj2 "19").tw,kw,kf. (11502)
- 106 ("coronavirus 2" or "corona virus 2").tw,kw,kf. (38199)
- 107 (OC43 or NL63 or 229E or HKU1 or HCoV* or Sars-coronavirus*).tw,kw,kf. (8144)
- 108 (coronavirus* or corona virus*).ti. (48015)
- 109 COVID.ti. (254131)
- 110 ("B.1.1.7" or "B.1.351" or "B.1.617" or "B.1.427" or "B.1.429").tw,kw,kf. (1406)
- 111 ("P.1" and (Brazil* or variant?)).tw,kw,kf. (3704)
- 112 (((alpha or beta or delta or eta or gamma or iota or kappa or lambda) adj3 variant?) and (coronavirus* or corona virus* or covid*)).tw,kw,kf. (461)

- 113 or/91-112 [COVID-19] (404957)
- 114 vaccination/ (246289)
- 115 ((COVID or COVID-19 or COVID19) adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kw,kf. (17544)

116 ((coronavirus* or corona virus*) adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kw,kf. (3913)

117 ((2019-nCoV or nCoV or n-CoV or SARS-CoV-2 or SARS-CoV2 or SARSCoV-2 or SARSCoV2 or SARS2 or SARS-2 or OC43 or NL63 or 229E or HKU1 or HCoV*) adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kw,kf. (9069)

118 (BNT162 or BNT162-01 or BNT162a1 or BNT162b1 or BNT162b2 or BNT162c2 or N38TVC63NU).tw,kw,kf. (1584)

- 119 (AZD1222 or ChAdOx1 or Covishield\$2 or B5S3K2V0G8).tw,kw,kf. (967)
- 120 (mRNA-1273 or EPK39PL4R4).tw,kw,kf. (596)
- 121 (mRNA adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kw,kf. (4944)
- 122 (messenger RNA adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kw,kf. (475)
- 123 LV-SMENP-DC.tw,kw,kf. (6)
- 124 (Ad5-nCoV or hAdOx1 nCoV-19).tw,kw,kf. (39)
- 125 ("Ad26.COV2.S" or Ad26COVS1 or JNJ 78436735 or JNJ-78436735 or JT2NS6183B).tw,kw,kf.

(195)

- 126 (Janssen adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kf. (142)
- 127 CX-024414.tw,kw,kf. (2)
- 128 (Moderna adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kw,kf. (483)
- 129 Spikevax\$2.tw,kw,kf. (11)
- 130 ((Pfizer or Pfizer-BioNTech) adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kf,kw. (1264)
- 131 (Comirnaty\$2 or Tozinameran\$2).tw,kw,kf. (202)
- 132 ((AstraZeneca or AZ or Oxford) adj5 (immunis* or immuniz* or inoculat* or vaccin*)).tw,kw,kf. (733)
- (133) 122 V
- 133 Vaxzevria\$2.tw,kw,kf. (119)
- 134 or/114-133 [VACCINES] (265426)
- 135 113 and 134 [COVID VACCINES PT 2] (27369)
- 136 90 or 135 [COVID VACCINES PTS 1 & 2] (29374)
- 137 virus vaccine/ae [adverse drug event] (999)

138 exp severe acute respiratory syndrome vaccine/ae [adverse drug event] (470)

139 ((immunis* or immuniz* or inoculat* or vaccin*) adj10 (adverse* or ADE or ADEs or ADR or ADRs or complication* or harm* or safe or safety or side effect? or undesirable effect? or undesirable consequence? or undesirable outcome? or unintended effect? or unintended consequence? or unintended outcome?)).tw,kw,kf. (76966)

140 ((post-vaccin* or post-immuni#ation* or post-innoculat* or after vaccin* or after immuni#ation* or after innoculat* or (following adj3 vaccin*) or (following adj3 immuni#ation*) or (following adj3 innoculat*)) adj10 (adverse* or ADE or ADEs or ADR or ADRs or complication* or harm* or safe or safety or side effect? or undesirable effect? or undesirable consequence? or undesirable outcome?)).tw,kw,kf. (6417)

141 ((post-vaccin* or post-immuni#ation* or post-innoculat* or after vaccin* or after immuni#ation* or after innoculat* or (following adj3 vaccin*) or (following adj3 immuni#ation*) or (following adj3 innoculat*)) adj10 (complication? or consequenc* or effect? or event? or harm* or outcome?)).tw,kw,kf. (7718)

- 142 (vaccine-associated or vaccine-induced or vaccine-related).tw,kw,kf. (20509)
- 143 (immuni#ation-associated or immuni#ation-induced or immuni#ation-related).tw,kw,kf. (1855)
- 144 exp pharmacovigilance/ (5254)
- 145 (pharmacovigilan* or pharmaco-vigilan*).tw,kw,kf. (18894)
- 146 (Canada Vigilance or Eudravigilance* or FAERS or VAERS).tw,kw,kf. (2780)

- 147 exp postmarketing surveillance/ (37209)
- 148 ((postmarket* or post-market*) adj3 surveillance*).tw,kw,kf. (9603)
- 149 phase 4 clinical trial/ (4491)
- 150 ((Phase 4 or Phase IV) adj3 (evaluation? or study or studies or trial?)).tw,kw,kf. (4910)
- 151 cardiomyopathy/ (90014)
- 152 (cardiomyopath* or cardio-myopath* or myocardiopath* or myo-cardiopath*).tw,kw,kf. (209222)
- 153 exp myocarditis/ (45666)
- 154 myocarditis.tw,kw,kf. (41845)
- 155 ((myocard* or myo-card) adj3 inflam*).tw,kw,kf. (12899)
- 156 carditis.tw,kw,kf. (4148)
- 157 exp pericarditis/ (31618)
- 158 pericarditis.tw,kw,kf. (27519)
- 159 ((pericard* or peri-card*) adj3 inflam*).tw,kw,kf. (1222)
- 160 epicarditis.tw,kw,kf. (249)
- 161 ((epicard* or epi-card*) adj3 inflam*).tw,kw,kf. (391)
- 162 (myopericarditis or myo-pericarditis).tw,kw,kf. (1763)
- 163 ((myopericard* or myo-pericard*) adj inflam*).tw,kw,kf. (25)
- 164 (pleuropericarditis or pleuro-pericarditis).tw,kw,kf. (412)
- 165 ((pleuropericard* or pleuropericard*) adj3 inflam*).tw,kw,kf. (13)
- 166 or/137-165 [MYOCARDITIS, PERICARDITIS] (483566)
- 167 136 and 166 [COVID-VACCINES MYOCARDITIS, PERICARDITIS] (6014)
- 168 exp animal/ or exp animal experimentation/ or exp animal model/ or exp animal experiment/ or nonhuman/ or exp vertebrate/ (54214081)
- 169 exp human/ or exp human experimentation/ or exp human experiment/ (42550990)
- 170 168 not 169 (11664830)
- 171 167 not 170 [ANIMAL-ONLY REMOVED] (5784)
- 172 editorial.pt. (1287357)
- 173 letter.pt. not (letter.pt. and randomized controlled trial/) (2336030)
- 174 171 not (172 or 173) [OPINION PIECES REMOVED] (5259)
- 175 limit 174 to yr="2020-current" (5170)
- 176 (202010* or 202011* or 202012* or 2021*).dc. (2457999)
- 177 175 and 176 [RECORDS PUBLISHED/ADDED SINCE OCT 2020] (2500)
- 178 177 use oemezd [EMBASE RECORDS] (2500)
- 179 89 or 178 [BOTH DATABASES] (5089)
- 180 remove duplicates from 179 (3235) [TÓTAL UNIQUE RECORDS]
- 181 180 use ppez [MEDLINE UNIQUE RECORDS] (2530)
- 182 180 use oemezd [EMBASE UNIQUE RECORDS] (705)

Cochrane Library

-	+	#1	[mth "COVID-19 Vaccines"]	Limits	55		
-	+	#2	[mh "COVID-19"]	Limits	657		
-	+	#3	[mh "SARS-CoV-2"]	Limits	479		
-	+	#4	[mh *Coronavirus]	Limits	4		
-	+	#5	ph *Betaceronavirus]				
-	+	#6	[mh *"Coronavirus Infections"]	Limits	657		
-	+	#7	("COVID-19" or COVID19):ti,ab,kw	Limits	7299		
-	+	#8	((coronavirus* or corona virus*) and (<u>hubei</u> or <u>wuhan</u> or <u>beijing</u> or shanghai)):ti,ab,kw	Limits	219		
-	+	#9	(wuhan NEAR/5 virus*):ti,ab,kw	Limits	9		
-	+	#10	("2019-nCoV" or 19nCoV) or 2019nCoV);ti,ab,kw	Limits	10		
-	+	#11	(<u>nCoV</u> or " <u>nCoV</u> or " <u>CoV</u> 2" or CoV2):ti,ab,kw	Limits	690		
-	+	#12	("SARS-CoV-2" or "SARS-CoV2" or "SARSCoV-2" or SARSCoV2 or SARS2 or "SARS-2" or "severe acute respiratory syndrome coronavirus 2"):ti,ab,kw	Limits	3039		
-	+	#13	("2019-novel Cov" or "Sars-coronavirus2" or "Sars-coronavirus-2" or "SARS-like coronavirus" or "SARS-like coronaviruses" or ((novel or new or nouveau) NEAR/2 (Cov or nov covid or coronavirus* or "corona virus" or " <u>Pandem</u> *2)) or (coronavirus* and pneumonia)).ti,ab,kw	Limits	1367		
-	+	#14	("novel coronavirus" or "novel coronaviruses" or "novel corona virus" or "novel corona viruses" or "novel CoV"):ti,ab,kw	Limits	478		
-	+	#15	((coronavirus* or "corona viruses") NEAR/2 "2019").ti,ab,kw	Limits	2503		
-	+	#16	((coronavirus* or "corona viruses") NEAR/2 "19").ti,ab,kw	Limits	299		
-	+	#17	("coronavirus 2" or "corona virus 2"):ti,ab,kw	Limits	765		
-	+	#18	(OC43 or NL63 or 229E or HKU1 or HCoV* or (Sats NEXT coronavirus*)):ti,ab,kw	Limits	84		
-	+	#19	(coronavirus" or "corona virus" or "corona viruses").ti	Limits	736		
-	+	#20	<u>COVID</u> ti	Limits	5641		

-	+	#21	("B.1.1.7" or "B.1.351" or "B.1.617" or "B.1.427" or "B.1.429");ti,ab,kw					
-	+	#22	("P.1" and (Brazil* or variant*)):ti,ab,kw	Limits	175			
-	+	#23	(((alpha or beta or delta or eta or gamma or iota or kappa or lambda) NEAR/3 variant*) and (coronavirus* or corona virus* or covid*)):ti, ab, kw	Limits	7			
-	+	#24	{or #2.#23}	Limits	7898			
-	+	#25	[mth Vaccination]	Limits	2680			
-	+	#26	((<u>CQVID</u> or "COVID-19" or COVID19) NEAR/5 (<u>immunis</u> * or	Limits	493			
-	+	#27	((coronavirus* or "corona viruse") NEAR/5 ((mmunis* or immuniz* or incculat* or vaccin*)):ti,ab,kw	Limits	100			
-	+	#28	(("2019-nCoV" or nCoV" or "n-CoV" or "SARS-CoV-2" or "SARS-CoV2" or "SARSCoV-2" or SARSCoV2 or SARS2 or "SARS-2" or OC43 or NL63 or 229E or HKU1 or HCoV") NEAR/5 (mmunist or immunist or inoculat or yaccint)):ti,ab,kw	Limits	221			
-	+	#29	(BNT162 or "BNT162-01" or BNT162a1 or BNT162b1 or BNT162b2 or BNT162c2 or N38TVC63NU):ti,ab,kw	Limits	38			
-	+	#30	(AZD1222 or ChAdOx1 or Covishield* or B5S3K2V0G8):ti,ab,kw					
-	+	#31	["mRNA-1273" or EPK39PL4R4):ti,ab,kw	Limits	24			
-	+	#32	(mRNA NEAR/5 (immunis* or immuniz* or ineculat* or yaccin*)).ti,ab,kw	Limits	100			
-	+	#33	("messenger RNA" NEAR/5 (immunix* or immunix* or inoculat* or vaccin*)).ti.ab.kw	Limits	24			
-	+	#34	"W.SMENE-DC":ti,ab,kw	Limits	0			
-	+	#35	["Ad5-nCoV" or "hAdOx1 nCoV-19"):ti,ab,kw	Limits	0			
-	+	#36	["Ad26.COV2.S" or Ad26COVS1 or "JNJ 78436735" or "JNJ-78436735" or JT2NS6183B):ti,ab,kw	Limits	22			
-	+	#37	(Japssen NEAR/5 (immunis* or immuniz* or ineculat* or vaccin*))-ti, ab, kw					
-	+	#38	"CX-024414":ti,ab,kw					
-	+	#39	(Moderna NEAR/5 (mmunia* or immunia* or inoculat* or vaccin*)):ti,ab,kw					
-	+	#40	Spilcevax*ti,ab.kw	Limits	0			
-	+	#41	((Pfizer or " <u>Pfizer:BioNTech</u> ") NEAR/5 (<u>immunis</u> * or <u>immuniz</u> * or <u>ineculat</u> * or <u>vaccin</u> *)):ti,ab,kw	Limits	47			
-	+	#42	(Cominaty* or Jazinameran*):tii,ab,kw	Limits	10			
-	+	#43	((AstraZenesa or AZ or Oxford) NEAR/5 (immunis* or immunis* or insculat* or vascin*)):ti,ab,kw	Limits	34			
-	+	#44	Xaxzerija*ti,ab,kw	Limits	6			
-	+	#45	{or #25:#44}	Limits	3419			
-	+	#46	#24 AND #45	Limits	638			
-	+	#47	#1 OR #46	Limits	638			
-	+	#48	[mth "COVID-19 Vaccines"/AE]	Limits	30			
-	+	#49	[mth *"Viral Vaccines"/AE]	Limits	221			
-	+	#50	[mth "Adverse Drug Reaction Reporting Systems"]	Limits	90			
-	+	#51	((immunis" or immuniz" or inoculat" or vaccin") NEAR/10 (adverse" or ADE or ADEs or ADR or ADRs or complication" or harm" or safe or safety or "side effect" or "side effects" or "undesirable effect" or "undesirable effects" or "undesirable consequence" or "undesirable consequences" or "undesirable editorme" or "undesirable outcome" or "undesirable outcome" or "undesirable consequences" or "unintended effect" or "unintended outcome" or "unintended outcome	Limits	12385			
-	#52 (((post NEXT vaccin*) or (post NEXT immunisation*) or (post NEXT immunization*) or (post NEXT immunisation*) or (after NEXT vaccin*) or (after NEXT immunisation*) or (after NEXT immunisation*) or (following NEAR3 vaccin*) or (following NEAR3 immunisation*) or (following NEAR3 immunisation*) or (after NEXT immunisation*) or (following NEAR3 vaccin*) or (following NEAR3 immunisation*) or "indesirable outcome* or "unidesirable outcome*" or "undesirable outcome*" or "unidesirable outcome*" or "unidesirable outcome*" or "unidesirable outcome*" or "unintended outcome*" or "		Limits	1493				
-	+	# #53 (((post NEXT vaccin*) or (post NEXT immunisation*) or (post NEXT immunization*) or (post NEXT immunisation*) or (after NEXT vaccin*) or (after NEXT vaccin*) or (after NEXT immunisation*) or (after NEXT immunisation*) or (following NEAR/3 vaccin*) or (following NEAR/3 immunisation*) or (following NEAR/3 vaccin*) or (following		Limits	1214			
-	+	#54	("vaccine-associated" or "vaccine-induced" or "vaccine-related"):ti,ab,kw	Limits	1451			
-	+	#55	("Immunisation-associated" or "immunisation-induced" or "immunisation-related" or "immunization-associated" or "immunization-induced" or "immunization-related") ti, ab, kw	Limits	38			
-	+	#56	((data or <u>vaccin</u>) NEAR/3 (monitor* or surveillance*)):ti,ab,kw	Limits	4798			
1		#57	[mb Pharmacovigilance]					

-	+	#58	(pharmacevigilan" or (pharmace NEXT vigilan")):ti,ab,kw				
-	+	#59	("Canada Vigilance" or <u>Eudravigilance</u> " or <u>FAERS</u> or <u>VAERS</u>);ti,ab,kw	Limits	19		
-	+	#60	[mh *"Product Surveillance, <u>Postmarketina</u> "]	Limits	100		
-	+	#61	2stmarket* or (post NEXT market*)) NEAR/3 surveillance*).ti,ab,kw				
-	+	#62	"Clinical Trial, Phase IV":pt	Limits	1201		
-	+	#63	(("Phase 4" or "Phase IV") NEAR/3 (evaluation* or study or studies or trial or trials));ti,ab,kw	Limits	2770		
-	+	#64	Imb *Cardiomyceathics1	Limits	677		
-	+	#65	(cardiomyopath* or (cardio NEXT myopath*) or myocardiopath* or (myo NEXT cardiopath*)):ti,ab,kw	Limits	4440		
-	+	#66	Loob Myssauditis]	Limits	93		
-	+	#67	myscarditis ti, ab, kw				
-	+	#68	((<u>myocard</u> * or (<u>myo</u> NEXT card*)) NEAR/3 jnfjam*).ti,ab,kw				
-	+	#69	<u>carditis</u> ti, ab, kw				
-	+	#70	[mth Pericarditis]	Limits	63		
-	+	#71	pericarditis:ti,ab,kw	Limits	349		
-	+	#72	((<u>gericard</u> * or (<u>geri</u> NEXT card*)) NEAR/3 internet ();ti,ab,kw	Limits	22		
-	+	#73	<u>eeiçarditis</u> -ti,ab,kw	Limits	2		
-	+	#74	((<u>epicacd</u> * or (<u>epi</u> NEXT card*)) NEAR/3 jnflam*).ti,ab,kw	Limits	5		
-	+	#75	(<u>myopericarditis</u> or " <u>myo-pericarditis</u> ").ti, ab, kw	Limits	12		
-	+	#76	((mxopericand* or (mxx NEXT pericand*)) NEAR/3 interventional (interventional intervention) (intervention) (int	Limits	1		
-	+	#77	(<u>eleuropericarditis</u> or <u>"eleuro-pericarditis</u> ").ti,ab.kw	Limits	3		
-	+	#78	((<u>gleuropericard</u> * or (<u>gleuro</u> NEXT <u>gericard</u> *)) NEAR/3 intern*).tii, ab.kw	Limits	0		
-	+	#79	(or #48#78)	Limits	27721		
-	+	#80	#47 AND #79	Limits	339		
			with Cochrane Library publication date from Oct 2020 to Oct 2021				

6-0ct-21

	Original Deduped	
MEDLINE	2530	2511
Embase	705	675
CDSR	2	0
CENTRAL	337	253
TOTAL	3574	3439

Appendix 2. Literature flow



Appendix 3. Supplements to Tables 2 and 3

Descriptions of surveillance systems used in studies within this report

CAEFISS: Managed by PHAC, monitors the safety of marketed vaccines in Canada through both passive and active reporting strategies. Reports are submitted by public health authorities in provinces and territories, who in turn receive them from local public health units. Provincial and territorial authorities also receive reports from federal authorities that provide immunization in their jurisdictions. Active surveillance is also carried out by 12 pediatric centres across Canada, which screen all hospital admissions for potential vaccine-related adverse events.

CVP: Passive surveillance program that collects reports of suspected adverse reactions to health products. Reports are submitted by health professionals and consumers on a voluntary basis either directly to Health Canada or to the market authorization holder, who in turn is required to submit reports of adverse events to Health Canada through the Canada Vigilance Program.

EudraVigilance: Passive surveillance system for the European Economic Area. Healthcare providers and patients can report any adverse effects from medical products, including vaccines. Patients, consumers and healthcare professionals report suspected side effects to either the national medicines regulatory authority or the pharmaceutical company that holds the marketing authorisation for the medicine. These reports are then transmitted electronically to EudraVigilance.

VAERS: Passive surveillance system for the United States, to which healthcare providers and patients can report adverse events from medical products, including vaccines. Providers are required to report to VAERS adverse events (including administration errors, serious adverse events, cases of multisystem inflammatory syndrome, and cases of COVID-19 that result in hospitalization or death) that occur after receipt of any COVID-19 vaccine.

Yellow Card: The Yellow Card scheme in the United Kingdom is a passive surveillance system to which anybody can voluntarily report any suspected adverse reactions or side effects to the vaccine. The reports are continually reviewed to detect possible new side effects that may require regulatory action, and to differentiate these from things that would have happened regardless of the vaccine or medicine being administered, for instance due to underlying or undiagnosed illness.

Study	Reference(s)		
Active Surveillance			
Clalit Health May 24a	Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19		
	Vaccination in a Large Health Care Organization. N Engl J Med.		
	2021. doi: <u>https://dx.doi.org/10.1056/NEJMoa2110737</u> .		
Clalit Health May 24b	Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the		
	BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N		
	Engl J Med. 2021;385(12):1078-1090.		
	doi: <u>https://dx.doi.org/10.1056/NEJMoa2110475</u> .		
Genesis Healthcare Jan 3	Bardenheier BH, Gravenstein S, Blackman C, et al. Adverse		
	events following mRNA SARS-CoV-2 vaccination among U.S.		
	nursing home residents. Vaccine. 2021;39(29):3844-3851.		
	doi: <u>https://dx.doi.org/10.1016/j.vaccine.2021.05.088</u> .		
Genesis HealthcareFeb 14	Bardenheier BH, Gravenstein S, Blackman C, et al. Adverse		
	Events Following One Dose of mRNA COVID-19 Vaccination		
	Among US Nursing Home Residents With and Without a		
	Previous SARS-CoV-2 Infection. J Am Med Dir Assoc.		
	2021;28:28. doi: https://dx.doi.org/10.1016/j.jamda.2021.08.024.		

References for included studies in question 1 labeled based on data sources

Study	Reference(s)
Israel MOH May 31	Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2
	mRNA Vaccine against Covid-19 in Israel. N Engl J Med. 2021.
lana di Dafana a Fana a Mara 7	doi: <u>https://dx.doi.org/10.1056/NEJMoa2109/30</u> .
Israell Defense Forces May /	Levin D, Shimon G, Fadion-Derai M, et al. Myocarditis following
	2021-39 Vaccination - A case series. Vaccine.
	doi:https://dx.doi.org/10.1016/j.vaccine.2021.09.004
KPSC Jul 20	Simone A. Herald J. Chen A. et al. Acute Myocarditis Following
	COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older.
	JAMA Intern Med. 2021;04:04.
	doi:https://dx.doi.org/10.1001/jamainternmed.2021.5511.
Providence Health May 25	Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV,
	Robicsek A. Myocarditis and Pericarditis After Vaccination for
	COVID-19. Jama. 2021;326(12):1210-1212.
	doi: <u>https://dx.doi.org/10.1001/jama.2021.13443</u> .
US Military Apr 30	Montgomery J, Ryan M, Engler R, et al. Myocarditis Following
	Immunization with mRINA COVID-19 Vaccines in Members of
	doi:https://dv.doi.org/10.1001/jamacardio.2021.2833
VSD Jun 26	Klein NP Lewis N. Goddard K. et al. Surveillance for Adverse
	Events After COVID-19 mRNA Vaccination, Jama, 2021:03:03.
	doi:https://dx.doi.org/10.1001/jama.2021.15072.
VSDAug 21	Klein NP. Rapid Cycle Analysis to Monitor the Safety of COVID-
5	19 Vaccines in Near Real-Time within the Vaccine Safety
	Datalink: Myocarditis and Anaphylaxis. Aug 30 Advisory
	Committee on Immunization Practices (ACIP)
	https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-
	<u>2021-08-30/04-COVID-Klein-508.pdf</u>
VSD Oct 6	Kieln NP. Myocarditis Analysis in the vaccine Safety Datalink:
	Comparisons 21 October 2021 2021 Advisory Committee on
	Immunization Practices (ACIP) Available from:
	https://www.cdc.gov/vaccines/acin/meetings/downloads/slides-
	2021-10-20-21/08-COVID-Klein-508.pdf.
Passive Surveillance	
CAEFISS & CVP	Public Health Agency of Canada. Canadian COVID-19
	vaccination safety report. Ottawa: Public Health Agency of
	Canada; October 18, 2021 2021. Available from: <u>https://health-</u>
	intobase.canada.ca/covid-19/vaccine-satety/#a4.
Eudra Vigliance Oct 19	European Medicines Agency. Eudravigliance - European
	database of suspected adverse drug reaction reports. European
	https://www.adrroports.gu/op/oudravigilanco.html. Published
	2021 Accessed October 26, 2021, 2021
Israel MOH May 30	Israel Ministry of Health, Surveillance of Mycocarditis
	(Inflammation of the Heart Muscle) Cases Between December
	2020 and May 2021 (Including). Available from:
	https://www.gov.il/en/departments/news/01062021-03
	Published 2021. Updated June 2, 2021. Accessed.

Study	Reference(s)			
VAERS Jun 11	Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine			
	COVID-19 Vaccine After Reports of Myocarditis Among Vaccine			
	Recipients: Update from the Advisory Committee on			
	Immunization Practices - United States, June 2021. MMWR			
	Morb Mortal VV KIY Rep. 2021;70(27):977-982.			
	dol: <u>nllps://dx.dol.org/10.15585/mmwr.mm/02/e2</u> .			
VAERS JUN Toa	mpey ID, Kiug A, Stevenson J, Manufola J. SARS-Cov-2 mpNA Vassingtion Associated Mysserditis in Children Ages 12			
	17: A Stratified National Database Analysis 2021			
	doi: https://dx.doi.org/10.1101/2021.08.30.21262866			
	Lazaros G. Anastassopoulou C. Hatziantoniou S. et al. A case			
	series of acute pericarditis following COVID-19 vaccination in the			
	context of recent reports from Europe and the United States.			
	Vaccine, 2021.			
	doi:https://dx.doi.org/10.1016/j.vaccine.2021.09.078.			
VAERS Jun 30	Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19			
	Vaccines After Reports of Adverse Events Among Adult			
	Recipients of Janssen (Johnson & Johnson) and mRNA COVID-			
	19 Vaccines (Pfizer-BioNTech and Moderna): Update from the			
	Advisory Committee on Immunization Practices - United States,			
	July 2021. MMWR Morb Mortal Wkly Rep. 2021;70(32):1094-			
	1099. doi: <u>https://dx.doi.org/10.15585/mmwr.mm7032e4</u> .			
VAERS Aug 6	Lane S, Shakir S. Reports of myocarditis and pericarditis			
	following mRNA COVID-19 vaccines: A review of spontaneously			
	reported data from the UK, Europe, and the U. 2021.			
	001. <u>111.ps://dx.doi.org/10.1101/2021.09.09.21263342</u> .			
VAERS OCIO	from the Vaccine Adverse Event Penerting System (VAEPS)			
	CDC October 21, 2021 2021, Available from:			
	https://www.cdc.gov/vaccines/acin/meetings/downloads/slides-			
	2021-10-20-21/07-COVID-Su-508.pdf.			
Yellow Card Oct 13	Medicine & Healthcare products Regulatory Agency.			
	Coronavirus vaccine - weekly summary of Yellow Card reporting.			
	Government of the United Kingdom. Available from:			
	https://www.gov.uk/government/publications/coronavirus-covid-			
	19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-			
	<u>vellow-card-reporting</u> . Published 2021. Updated October 21,			
	2021. Accessed October 21, 2021, 2021.			
Randomized Controlled Trials	Falses AD Oskieszende ME Llinsek Let al Dhase 2 Osfatuend			
AZD1222 Inal, Phase 3	Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 Salety and			
(Astrazeneca)	Enilcacy of AZD 1222 (CHAQOX 1 HCOV-19) COMO-19 Vaccine. IN			
	doi:https://dx.doi.org/10.1056/NE IMoa2105290			
AZD1222 Trial Pooled Analysis	Vovsey M. Clemens SAC, Madhi SA, et al. Safety and efficacy of			
(AstraZeneca)	the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-			
	2: an interim analysis of four randomised controlled trials in			
	Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-			
	111. doi: https://dx.doi.org/10.1016/S0140-6736(20)32661-1.			
	Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose			
	administration and the influence of the timing of the booster dose			
	on immunogenicity and efficacy of ChAdOx1 nCoV-19			
	(AZD1222) vaccine: a pooled analysis of four randomised trials.			
	Lancet. 2021;397(10277):881-891.			
	doi: <u>https://dx.doi.org/10.1016/S0140-6736(21)00432-3</u> .			

Study	Reference(s)
C4591001 Trial, Adolescent	Frenck RW, Jr., Klein NP, Kitchin N, et al. Safety,
cohort (Pfizer)	Immunogenicity, and Efficacy of the BNT162b2 Covid-19
	Vaccine in Adolescents. N Engl J Med. 2021;385(3):239-250.
	doi: <u>https://dx.doi.org/10.1056/NEJMoa2107456</u> .
C4591001 Trial, Adult cohort	Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of
(Pfizer)	the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med.
	2020;383(27):2603-2615.
	doi: <u>https://dx.doi.org/10.1056/NEJMoa2034577</u> .
	Thomas SJ, Moreira ED, Jr., Kitchin N, et al. Safety and Efficacy
	of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N
	Engl J Med. 2021;15:15.
	doi: <u>https://dx.doi.org/10.1056/NEJMoa2110345</u> .
COVE trial (Moderna)	Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of
	the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med.
	2021;384(5):403-416.
	doi:https://dx.doi.org/10.1056/NEJMoa2035389.
	El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-
	1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N
	Engl J Med. 2021.
	doi: <u>https://dx.doi.org/10.1056/NEJMoa2113017</u> .
Teen COVE trial (Moderna)	Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273
	SARS-CoV-2 Vaccine in Adolescents. N Engl J Med.
	2021;11:11. doi: <u>https://dx.doi.org/10.1056/NEJMoa2109522</u> .
ENSEMBLE Trial (Janssen)	Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of
	Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J
	Med. 2021;384(23):2187-2201.
	doi: <u>https://dx.doi.org/10.1056/NEJMoa2101544</u> .

Appendix 4: Study Characteristics Tables and Risk of Bias Tables

Table A1. Study characteristics of observational studies using data from active surveillance systems (question 1)

Dataset	Vaccines	Sample Size;	Study Group(s)	Outcome(s);Risk	Analysis	Results
Dates	Studied	Demographics;		Interval; Case	_	
Country		Previous Covid-19		Ascertainment		
		diagnoses				
VSD [†] Oct 9	Pfizer-	Total doses 14,214,955	1. Vaccinated in previous	Myocarditis/pericarditis/	Weekly, rapid cycle	Events: 138 (not confirmed) after either dose
	BioNTech	(71.5% eligible people	0-21 d	myopericarditis (combined	analysis	Incidence: 138/14,214,955 = 9.7 per million doses
Dec 14 2020 to	(60% of	fully vaccinated) to 7.5	2. Concurrent previous	& separate for head-to-		alRR: 1.72 p <.001 (statistical signal)
Oct 9	dose 2) or	million people	vaccinees (22 to 42 d	head comparison)	Adjusted incident rate	
	Moderna		previously for similar	. ,	ratio (aIRR) estimated by	Exploratory analyses:
USA		NR	individuals after vaccine	ICD-10 using inclusion and	Poisson regression	
			dose 1 or 2 [most dose	exclusionary codes via	adjusted for age, sex,	12-39 y (all confirmed cases)
(Klein, 2021a)		Excluded from analysis if	2])	clinical expert consultation;	race and ethnicity, health	
, , ,		COVID-19 diagnosis ≤30	-/	cases among 12-39 y	plan, and calendar day;	Group 1: 74 cases in 0-21 d interval (59 [80%] after dose 2; 39 [53%
		d before vaccination	Interval between doses:	confirmed by medical	1-sided P < .0048 for	in 0-7 d)); 44 (59%) in 18-39 y and 30 (40.5% in 12-17 y
			majority 21 d (Pfizer) and	record review	statistical signal	
			28 d Moderna)		_	Clustering at 0-5 d after vaccine (p<.0001)
				ED and in-patient records	Excess risk/incidence	
				used	per million doses (IR –	0-7 d risk interval
					[IR/IRR])	aIRR (95% CI) Excess risk per million doses
				Blinding to vaccine status		Both doses 21.73 (9.53 to 57.34) 11.8
				NR	Exploratory analyses	Dose 2 31.28 (12.83 to 91.40) 21.1
					(no prespecified level of	
				Risk interval: 0-21 d & 0-7	significance): by dose	Pfizer (<u>12-39y</u>) 19.31 (7.66 to 57.79) 11.5
				d	and vaccine type; for 12-	Dose 2 30.27 (11.01 to -104.4) 21.5
					39 y by dose, vaccine	
					type and with shorter risk	Moderna (<u>18-39y</u>) 37.51 (6.69 to 803.00) 12.8
					intervals; head-to-head	Dose 2 NE (11.75 to NE) 21.0
					Moderna vs Pfizer in 18-	
					39 y (also excluded	(For dose 1: alRR range 8.7-10.5, all significant; excess cases 2.3-
					pericarditis)	5.2)
						0-7 d risk interval (<i>18-39 y only</i>)
						alRR (95% Cl) Excess risk per million doses
						Both doses 12.61 (5.27 to 34.47) 8.4
						Dose 2 14.33 (5.50 to 43.88) 13.1
						Pfizer 7.98 (2.72 to 26.50) 5.7
						Dose 2 8.77 (2.56 to 35.34) 8.5
						Moderna 37.42 (6.68 to 801.33) 12.8
						Dose 2 NE (11.70 – NE) 21.0

Dataset	Vaccines Studie d	Sample Size;	Study Group(s)	Outcome(s); Risk	Analysis	Results
Dates Country	Studied	Demographics; Previous Covid-19		Ascertainment		
Country		diagnoses				
						(For dose 1: alRR range 8.05 to 10.47; all significant; excess cases 3.3 to 5.2)
						0-7 d risk interval (12-17 y only)
						Pfizer NE (16.88 to NE) 29.6 Dose 2 NE (28.83 to NE) 54.0
						0-21 d risk interval (12-17 y on/y) alRR (95% Cl) Excess risk per million doses
						Pfizer NE (5.68 to NE) 29.6 Dose 2 NE (9.09 to NE) 56.7
						Head-to-head Moderna vs Pfizer in 18-39 y
						(0-7 d) alRR Excess risk per million doses Both doses 2.56 (1.32 to 5.03) 8.0 Dose 2 2.72 (1.25 to 6.05) 13.3
						Dose 2 (males) 2.26 (1.00 to 5.19) 21.5
						(0-21 d) alRR Excess risk per million doses Both doses 2.05 (1.11 to 3.83) 7.1 Dose 2 2.19 (1.05 to 4.65) 11.5
						Dose 1 all nonsignificant
						Head-to-head Moderna vs Pfizer in 18-39 y (without pericarditis) alRR Excess cases per million doses
						(0-7 d) Both doses 2.24 (1.09 to 4.63) 5.6 Dose 2 2.28 (1.25 to 6.05) 13.3 Dose 2 (males) 2.14 (0.93 to 4.98) 19.1
						(0-21 d)
						Both doses 1.96 (0.99 to 3.91) 5.3 Dose 2 2.19 (0.98 to 4.97) 9.4 Dose 1 all nonsignificant 0.4
VSD [†] Aug 21	Pfizer- BioNTech	Total doses 13,334,831 (66.5% fully vaccinated)	1. Vaccinated in previous 0-21 d	Myocarditis/pericarditis/ myopericarditis (combined) Rick interval: 0.21 d		Events: 115 alRR: 1.57 p=0.010 (not meeting p<0.0048 signal)
Aug 21 2020 to	overall) or Moderna		vaccinees (22 to 42 d previously for similar	TUSK IIILEIVAI. U-21 U		Subgroups:

Dataset	Vaccines	Sample Size;	Study Group(s)	Outcome(s);Risk	Analysis	Results
Dates	Studied	Demographics;		Interval; Case		
Country		Previous Covid-19		Ascertainment		
		diagnoses				
USA			individuals after vaccine			12-39 y
			dose 1 or 2 [most dose			56 cases in 0-21 d risk interval
(Klein 2021b)			2])			aIRR Excess risk per million doses
						Both doses 5.63 (2.31 to 16.44) 8.9
						Dose 2 8.31 (3.07 to 28.28) 15.5
						Pfizer 3.62 (1.39 to 11.11) 7.2
						Dose 2 5.74 (1.98 to 20.52) 13.6
						Moderna NE (3.32 to NE) 12.7
						Dose 2 NE (3.79 to NE) 19.8
						Dose 1 aIRR 2.3 to 3.8 and imprecise for separate vaccines
						For 0-7 risk interval – see more recent data in Klein Oct 21, 2021
VSD [†] Jun 26	Pfizer-	10,162,227 doses to 6.2	1. Vaccinated in previous	Myocarditis/pericarditis/	Weekly, rapid cycle	Group 1 vs. 2
	BioNTech	million vaccine-eligible	0-21 d	myopericarditis (combined)	analysis	Events: 87 vs 39 events
Dec 14 2020 to	(57%	members (≥12 y) (60.7%	2. Concurrent previous		-	Incidence: 131.1 vs. 106.9 per million person-years
Jun 26 2021	overall) or	received at least 1 dose)	vaccinees (22 to 42 d	Risk interval: 0-21 d and 0-	Incidence after any dose,	alRR: 1.18 (95% Cl, 0.79 to 1.79)
	Moderna		previously for similar	7 d	after dose 1 and after	Excess risk/cases per million doses: 1.2 (95% Cl, -2.1 to 3.3)
USA		Females 52.4%	individuals after vaccine		dose 2	
		Mean age 49 y; 5.5%	dose 1 or 2 [most dose	ICD-10 using inclusion and		Exploratory analyses:
Klein 2021c		12-15 y; 2.8%16-17 y;	2])	exclusionary codes via	Incident rate ratio (IRR)	
		50.4% 18-49 y	3. Unvaccinated	clinical expert consultation;	estimated by Poisson	By dose and vaccine type: p > 0.0048 for all
		White non-Hispanic	concurrent comparators	cases among 12-39 y	regression adjusted for	
		40.6%	(same day)	confirmed by medical	age, sex, race and	12-39y:
				record review	ethnicity, health plan,	34 cases (53% 12-24y; 85% male; 82% hospitalized; 71% after dose
		Excluded from analysis if	Interval between doses NR		and calendar day; 1-	2; 7 myocarditis; 6 pericarditis; 21 myopericarditis)
		COVID-19 diagnosis ≤30		ED and in-patient records	sided P < .0048 for	Clustering at 0-5 d after vaccine (p<.001)
		d before vaccination		used	statistical signal	During 0-21 d after vaccination (either dose):
					Francisco de la finaciada en a	incidence: 141.2 vs. 35.0 cases per million person-years
				Blinding to vaccine status	Excess risk/incidence	alKR: 3.74 (95% Cl, 1.38 to 12.84)
				NR	per million doses (IR –	Similar results for each dose but most precise for dose 2 having
						more data
					Fundameters, analysis	During U-7 d arter vaccination (either dose):
					Exploratory analyses	Incluences: 321 Vs 35 cases per million person-years
					(no prespecified level of	dirtr . 9.83 (95% U, 3.35 10 35.77)
					significance): by dose	Excess risk per million doses: 6.3 (95% UI, 4.9 to 6.8)
					and vaccine type; for 12-	Similar results for each dose but most precise for dose 2 having
					by by dose, vaccine	nure udla Similar, findings in analyses by vaccine type
						Similar minumus in analyses by vaccine type
					intervals	

Dataset	Vaccines	Sample Size;	Study Group(s)	Outcome(s);Risk	Analysis	Results
Dates	Studied	Demographics;		Interval; Case		
Country		Previous Covid-19		Ascertainment		
-		diagnoses				
						Group 1 vs 3:
						Events: 87 vs. 293
						Incidence 132 vs. 83 cases per million person-years
						alRR: 1.39 (95% Cl. 1.05 to 1.82)
US Military Apr	Pfizer-	2 810 00 doses (38%	1 Vaccinated	Myocarditis	Incidence in vaccinated	Events: 23 (20 after dose 2)
30	BioNTech	dose 2)	2 Expected numbers	ing ocal aldo		
00	or Moderna	4000 2)	within 30 d after	Cases identified via	Observed vs expected	Observed vs expected:
lan 1 to Apr 30		Males 100%	vaccination	referrals to Defense Health	cases: expected number	Total doses: 23 v vs 2 to 52
2021		Modian ago 25 (20 51)	Vaccillation	A goney clinical specialists	based on an expected humber	Dec. 2: 20 yr 1 to 20
2021		Median age 23 (20-51)		and through review	appual incidence ranging	Dose 2 to military members: 10 vs 0 to 10
		Tested cases for Covid		of VAEPS reports: each	from 1 10 por 100 000	Dose 2 to male military members: 19 vs 0 to 10
USA						Dose 2 to male military members. 19 vs 0 to 0
Montgomony		ofter doop 2 (n=2) had		CDC definition for	person-years (03) to 22	Insidence:
		arter dose 2 (II-3) had			per 100 000 person-	Total deses: 0.9 per 100.000 deses
2021		previous Covid-19		probable	years (internationally);	
				Diele intervels all mass anterel	presenting within a 30-	Dose 2: 1.9 per 100,000 doses
				Risk interval: all presented	day period after	Dose 2 to military members: 3.5 per 100,000 doses
				within 4 d	vaccination.	Dose 2 to male military members: 4.4 per 100,000 doses
Providence	Pfizer,	N=2,000,287	1. Individuals vaccinated	Myocarditis, Pericarditis	Change/excess in	Excess incidence of myocarditis/myopericarditis: 1.0 (0.61-1.54) per
Health May 25	Moderna,		with at least 1 dose	w /o myocarditis	incidence between	100,000 vaccinees
	Janssen	Female 58.9%	2. Unvaccinated		periods	Excess incidence of pericarditis: 1.8 (1.30-2.55) per 100,000
Up to May 25		Median age 57	individuals Jan 19 –	Emergency department or		vaccinees
2021	At least	y (IQR 40-70)	Jan21	inpatient encounters with		
	one dose			diagnoses of myocarditis/		
USA	(23.5%			myopericarditis, or		
	more than			pericarditis		
Diaz 2021	1)					
				Patients with previous		
				diagnoses (cardiac,		
				immunological, infectious)		
				excluded		
				Risk interval: 30d		
KPSC Jul 20	BNT162b2	KPSC members ≥18y	1. Vaccinated	Myocarditis	Incidence rates and 95%	Observed incidence:
	(Pfizer) or	Vaccinated group	2. Concurrent	-	confidence intervals	Dose 1: 0.8 (0.2-3.3) cases per 1 million first doses
Dec 14 2021 to	mRNA-	n=2,392,924	unvaccinated	Reports from clinicians to	(Cls)	Dose 2: 5.8 (3.4-10) cases per 1 million second doses
Jul 20 2021	1273		3. Vaccinated individuals	the KPSC Regional		Unvaccinated: 2.2 (1.7-2.7) cases per million people
	(Moderna)	Median age 49y (IQR:	during a 10-day period 1	Immunization Practice	IRR 1 vs 2, 1 vs 3	
USA	(93.5%	34-64y)	year prior to vaccination	Committee and by		100% cases men
	fullv	Age <40 v: 35.7%		identifying hospitalization		
Simone 2021	vaccinated)	5,		within 10 days of vaccine		IRR (95% CI): 1 v 2
		Females 54.0%		administration with a		Dose 1: 0.38 (0.05-1.40)
						Dose 2: 27 (14-48)
L			I			

Dataset	Vaccines	Sample Size;	Study Group(s)	Outcome(s);Risk	Analysis	Results
Dates	Studied	Demographics;		Interval; Case	-	
Country		Previous Covid-19		Ascertainment		
, ,		diagnoses				
		Black 6.7%: Hispanic		discharge diagnosis of		
		37.8%: Asian 14.3%		myocarditis		IRR 1 v 3
						Dose 1: 1.0 (0.1-13.8)
		Unvaccinated group:		All cases were		Dose 2: 3.3 (10-13.7)
		n=1 577 741 median				
		(IOR) are was $39/28$		by at least 2 cardiologists		
		53) years				
		$\Delta q_{0} < 40 \times 53.7\%$		Pisk interval: 10d		
		Age ~40y. 55.1 /6		NSK INCIVAL TOU		
		Females: 49 1% Black				
		8.8%: Hispanic 39.2%:				
		Asian 6.6%				
Israel MOH*	Pfizer-	Surveillance population	1. Received dose 1	Mvocarditis/mvopericarditis	Incidence in aroups 1	Total events in groups 1 and 2: 142 (136 definitive or probable [117
May 31	BioNTech	9,289,765 Israeli	(n=5.442.696)	,	and 2 (cumulative risks)	after dose 21, used for analysis except for standardized IR); group 3;
		residents ≥16 v	2 Received dose 2	ICD-9 codes 422 0-9x and	Risk difference	101
Dec 20 2020 to	2 doses to		(n=5,125,635)	429.0x: cases 12-29 vrs	(incidence) between 1 vs	
May 31 2021	5 12 million	29 of 98 cases in	3 Concurrent	old confirmed by medical	2	Incidence: dose 1: 0.35 per 100.000 persons: dose 2: 2.28 per
111dy 01 2021	neonle			record review using	Standardized incidence	100.000 persons
Israel	people	had confirmed Covid-19	matched by date	Brighton Criteria via	ratio of observed-to-	
151001		(timing NR): NR for	4 Historical controls from	consensus	expected (historical	Risk difference dose $2 - dose 1 \cdot 1.76$ per 100.000 persons (95% Cl
Meyorach		vaccinated	2017-2019	Concernede	controls)	1 33 to 2 10)
2021		Vaccillated	2017-2013	Assessors not blinded to	Attributable risk to dose	1.55 to 2.15)
2021		Age sex race/ethnicity	Interval between doses 21			Standardized incidence ratio: group 1 vs / 1 /2 (95% CL 0 92 to
		NR	d	vaccine status		2 10): group 2 vs $4:534$ (95% CL 4.48 to 6.40)
			ŭ	Cases of pericarditis	(weighted by age and	2.10), group 2 vs 4. 0.04 (00/0 0), 4.40 to 0.40)
				without myocarditis were	(weighted by age and	alRR_group 2 vs 3: 2 35 (95% Cl = 1 10 to 5 02)
		None of the post-		excluded	00,00	
		vaccination cases had			Subgroups: sex 5-yr age	Subgroup analyses
		concurrent Covid-19 via		Risk interval: 21 d for dose	categories <30 10 yr	Males vs females:
		symptoms or PCR		1 and 30d for dose 2	after 30. shorter risk	Incidence.
		35/39 had negative			interval 0-7 d	dose 1:0.64 vs.0.07 per 100.000 persons
		serology tests				dose 2: 3.83 vs. 0.46 per 100,000 persons
		scrology lesis				Risk difference dose 2 – dose 1: 3 10 (05% CL 2 37 to 4.02) vs. 0.30
						(95% CL 0 10 to 0.68)
						(35% O, 0.10 to 0.00)
						By age, categories:
						Males
						Dose 1 incidence per 100 000 persons
						16-19 v 1.34
						20-24 y 1 91
						25-29v 1.22
						30-39 v 0.41

Dataset	Vaccines	Sample Size;	Study Group(s)	Outcome(s);Risk	Analysis	Results
Dates	Studied	Demographics;		Interval; Case		
Country		Previous Covid-19		Ascertainment		
		diagnoses				
						40-49y 0.65
						≥50y 0.10
						Dose 2 incidence
						16-19 y 15.07
						20-24 y 10.86
						25-29 y 6.99
						30-39 y 3.69
						40-49 y 1.15
						≥50 y 0.21
						alRR 16-19 y 8.96 (95% Cl, 4.50 to 17.83); 20-24 y 6.13 (95% Cl
						3.16 to 11.88); 25-29 y 3.58 (95% Cl 1.82 to 7.01); ≥30 y 1.00
						(95% Cl, 0.61 to 1.64)
						Females
						Dose 1 incidence
						16-39 y 0
						40-49 y 0.21
						≥50 y 0.09
						Dose 2 incidence
						20-24 y 2.10
						20-29 9 0
						30-39 9 0.22
						40-49 9 0.45
						≥20 y 0.19
						IRR 20-24 y 7.56 (95 Ci, 1.47 to 6.96), others imprecise
						Shorter risk interval (7 d after dose 2)
						Males 16-19 v:
						Risk difference: 13.62 per 100.000 persons (95% CL 8.31 to 19.03)
						IRR: 31.90 (95% Cl, 15.88 to 64.08)
Clalit Health**	Pfizer-	2,558,421 ≥16 y	1. Received 1 dose	Myocarditis	Incidence after dose 1 or	Events: 54 (of 159 potential cases; 37 after dose 2; with 17/37 >7
May 24a	BioNTech	receiving at least 1 dose	(n=2,558,421)	-	2 using Kaplan–Meier	days post dose 2)
-		(94% 2 doses)		Risk interval: 42 d after	analysis	
Dec 20 2020 to	94%		Interval between doses 21	dose 1	-	Incidence: 2.13 cases per 100,000 persons (95% Cl: 1.56 to 2.70)
May 24 2021	received 2	2 cases had Covid-19	d		Subgroups: Sex; Ages	
	doses	(125 and 186 d) prior to		ICD-9 (codes 422, 429.0,	16-29 y; ≥30 y	Subgroup analysis
Israel		vaccine but NR if any		398.0, and 391.2 and their		Males vs females:
		others and NR if active		respective subcodes), with		Incidence: 4.12 (95% CI: 2.99 to 5.26) vs. 0.23 (95% CI: 0 to 0.49)
Witberg, 2021		testing of cases		adjudication by		
		2		cardiologists using medical		By age categories:
				and CDC case definition,		Overall 16-29 y: 5.49 per 100,000 persons (95% Cl: 3.59 to 7.39)
				w ith consensus		Overall ≥30 y: 1.13 per 100,000 persons (95% Cl: 0.66 to 1.60)
						Males 16-29 y: 10.69 per 100,000 persons (95% Cl: 6.93 to 14.46)

Dataset	Vaccines	Sample Size;	Study Group(s)	Outcome(s);Risk	Analysis	Results
Dates	Studied	Demographics;		Interval; Case		
Country		Previous Covid-19		Ascertainment		
-		diagnoses				
				Unblinded to vaccine		Males ≥30 y: 2.11 per 100,000 persons (95% Cl, 1.19 to 3.04)
				status (all vaccinated and		Females 16-29 y: 0.34 per 100,000 persons (95% Cl, 0 to 1)
				author adjudicating)		Females ≥30 y: 0.20 per 100,000 persons (95% Cl, 0 to 0.48)
Clalit Health**	Pfizer-	Surveillance population	1. Received 1 dose	Myocarditis & pericarditis	Incidence using Kaplan-	Events in group 1 vs 2: myocarditis 21 (91% male; median age 25y
May 24b	BioNTech	1,877,624 ≥16 y	(n=884,828)	after at least 1 dose	Meier estimator	[IQR 20-34]) vs 6; pericarditis: 27 vs 18
		-	2. Concurrent			
Dec 20 2020 to	NR how	Excluded people with	unvaccinated, matched	Risk interval: 42 d after	Risk difference	Risk difference (all ages): myocarditis: 2.7 events per 100,000
May 24 2021	may had 1	previous events, residing	1:1 by age, sex, place of	dose 1	Risk Ratio	persons (95% Cl, 1.0 to 4.6); pericarditis: 1.0 events per 100,000
,	vs 2 doses	in nursing homes,	residence,			persons (95% Cl, -1.6 to 3.4)
Israel		healthcare workers, no	socioeconomic status,	ICD-9 codes (422, 429.0,		
		BMI or residential area	population sector	398.0, 391.2, 420) after		RR: myocarditis: 3.24 (95% Cl, 1.55 to 12.44); pericarditis: 1.27
Barda, 2021		data	(general Jew ish, Arab, or	the index date		(95% Čl, 0.68 to 2.31)
			ultra-Orthodox Jewish),			
		Mean age 38 y	number of preexisting	Blinding NR		
		Females 48%	conditions at risk for	-		
			severe Covid-19.			
		Previous Covid-19 cases	(n=884,828)			
		excluded				
			Interval between doses 21			
			d			
Israeli Defense	Pfizer-	138,000	1. Vaccinated with 2 doses	Myocarditis	Crude cumulative	Events: 7 confirmed in risk interval (100% male; Age 18-24)
Forces May 7	BioNTech		(n=138,000)	5	incidence	
		NR		Medical record review,		Incidence: 5.07 per 100,000 people
Dec 28 2020 to	138,000		Interval between doses NR	requiring ECG,		
Mar 7 2021	military	NR		echocardiography, or MRI		
	personnel			findings		
Israel	receiving 2			-		
	doses			Risk interval: 7 d after		
Levin, 2021				dose 2		
				Not blinded		
Genesis	Moderna or	20,918 nursing home	1. No prior infection at	Myocarditis/pericarditis	Incidence (if events)	Events: group 1 vs 2 vs 3: 0 vs. 0 vs. 0
Healthcare***	Pfizer-	residents	vaccination (n=13.163)			
Feb 14	BioNTech		2. Symptomatic infection	Risk interval: 15 days after	Comparisons between	
		Females 61.9%	>20 days before	dose 1	groups by multilevel	
Dec 18 2020 to	All had 1	<65 y 18.5%	vaccination (n=5,617)		logistic regression that	
Feb 14 2021	dose	African American or	3. Asymptomatic infection	Active, prospective	adjusted for clustering	
		Latinx 16.9%	>20 days before	surveillance; medical	and applied propensity	
USA			vaccination (n=2,138)	record review for ICD-10-	scoring for age, sex, pre-	
		Excluded if Covid-19	4. Unvaccinated (from	CM codes, confirmed by	existing conditions	
Bardenheier,		+ve within 20 d of	Bardenheier, 2021b)	physician chart review,		
2021a		vaccination, or treated		using Brighton		
			Interval between doses NA	Collaboration Criteria	<u> </u>	

Dataset	Vaccines Otudio d	Sample Size;	Study Group(s)	Outcome(s); Risk	Analysis	Results
Dates	Studied	Demographics;		Interval; Case		
Country		diagnosos		Ascertainment		
		with SAPS CoV 2				
		monoclonal antibodies		Blinding NP		
		within 90 days before				
		vaccination				
Genesis	Moderna or	21 222 pursing home	1 After dose 1 ($n=8553$)	Muccarditis	Incidence	Evente: 0 ve 0 ve 0
Healthcare***		residents	2 After dose 2 $(n=8371)$	Wy ocar ditto	Incidence	
lon 3	BioNTech	residents	3 Unvaccinated $(n=11072)$	Active prospective	IRR adjusted for age	
Jan J	(70.6%)	Females 61.9%	5. Onvaccinated (II=11072)	surveillance: medical	sex pre-existing	
Dec 18 2020 to	(10.070)	<65 v 18 8	Interval between doses 3	record review for ICD-10	conditions	
Jan 3 2021	1 st dose or	African American or	to 6 w eeks	codes, confirmed by	Contailiono	
	2 nd dose	Latinx 18%		physician chart review.		
USA				using Brighton		
-		Excluded if Covid-19		Collaboration Criteria		
Bardenheier,		+ve within 20 d of				
2021b		vaccination, or treated		Blinding NR		
		with SARS-CoV-2		Ũ		
		monoclonal antibodies				
		within 90 days before				
		vaccination				

Dataset	Vaccines Studied	Outcome(s); Case Ascertainment &	Analysis	Results					
Dates of data		RISK INTERVAL							
VAERS* Oct 6	Pfizer-BioNTech,	Myopericarditis (myocarditis +/-	Crude reporting rates of	Total events: 2,459 myopericarditis (1,181 have been verified and 935 occurred in 0-6 d after					
	Moderna and Janssen	pericardtis); pericarditis	confirmed cases of	vaccination; 877 pericarditis (366,062,239 doses of mRNA vaccines)					
Up to Oct 6, 2021			myopericarditisafter each dose	For myopericarditis: 67% Pfizer: 29% Moderna: 76% after dose 2 (50 preliminary reports after Janssen					
USA		Screening via 30 MedDRA terms and ICD-10; all analyzed reports verified to		not in analysis)					
Su, 2021		meet CDC case definition by provider interview or medical record review		Reporting rates of myopericarditis per 1 million doses administered (N=935 verified cases):					
				Ages Dose 1 Dose 2 Dose 1 Dose 2					
		Risk interval: 7 d		12-15 2.3* 21.5 0.0 not calculated					
				16-17 2.8 37.4 0.0 not calculated					
				18-24 1.2 18.1 3.1 20.7					
				25-29 0.7 5.7 1.8 11.2 30.30 0.6 2.9 1.4 3.6					
				30.59 0.0 2.6 1.4 3.6 3					
				50-64 0.3 0.4 0.5 0.5					
				65+ 0.1 0.2 0.0 0.3					
				Males(N=797)					
				Ages Dose 1 Dose 2 Dose 1 Dose 2					
				12-15 4.2 39.9 0.0 not calculated					
				16-17 5.7 69.1 0.0 not calculated					
				18-24 2.3 36.8 6.1 38.5					
				25-29 1.3 10.8 3.4 17.2					
				30-39 0.5 5.2 2.3 6.7					
				50.64 0.2 0.3 0.5 0.6					
				65+ 0.2 0.1 0.1 0.3					
				Females(N=138)					
				Ages Dose 1 Dose 2 Dose 1 Dose 2					
				1Ž-15 0.4 3.9 0.0 0.0					
				16-17 0.0 7.9 0.0 0.0					
				18-24 0.2 2.5 0.6 5.3					
				25-29 0.2 1.2 0.4 5.7					
				4049 ± 0.1 1.1 0.2 1.4 50.64 0.3 0.5 0.5 0.4					
				65+ 0.1 0.3 0.0 0.3					
				*Reporting rates exceed background incidence (bolded data above))					
				An estimated 1–10 cases of myocarditis per 100,000 person years occurs among people in the United					
				States, regardless of vaccination status: adjusted for the 7-day risk period, this estimated background is					
				0.2 to 1.9 per 1 million person 7-day risk period					
VAERS* Jun 30	Pfizer-BioNTechor Moderna	Myocarditis	Crude reporting rates after dose 2	Overall ≥18 yrs: 3.5 cases per million second doses					
Up to Jun 30 2021				Subgroups (all after dose 2):					
			Subgroups by age and sex						

Dataset Dates of data	Vaccines Studied	Outcome(s); Case Ascertainment & Risk Interval	Analysis	Results
Country of Data				
USA	After dose 2, timing	Cases in persons aged 18–29 yrs were		Females
Besenhlum 2021	NR	individually reviewed and confirmed to		18-29 yrs: 3-4 cases per million second doses
Rosenblum, 2021		meet CDC case definitions		30-49 yrs 1-2 cases per million second doses
		Risk interval: 42 d		365 vrs <1 case per million second doss
				Males
				18-29 yrs: 22-27 cases per million second doses
				50.64 yrs: 1 case per million second does
				≥65 yrs: 1 case per million second doses
VAERS* Jun 11	Pfizer-BioNTech or	Myocarditis	Crude reporting rates (i.e.,	Males 12-29 yrs: 40.6 cases per million second doses
Up to Jup 11 2021	Moderna	Noto: Subset of confirmed cases	using confirmed and	Males 12-17 yrs 62.8 cases per million second doses
00 10 3011 11 2021	Afterdose 2 timina	described and included in KO2	dose 2	Males >30 yrs 24 cases ner million second doses
USA	NR		40002	Females 12-29 vrs: 4.2 cases per million second doses
		Risk interval: 7 d		Females≥30 yrs: 1.0 cases per million second doses
Gargano 2021				
VAERS* Aug 6	Pfizer-BioNTech,	Myocarditis and pericarditis	Crude reporting ratesper	
Lip to Aug 6 2021	Moderna	Eventaleballed "Myccorditic" or	million people receiving at	Prizer/BioNiech: 7,93 cases of myocarditisand 6,73 cases pericarditis per million vacchees
Op to Aug 8 202 1	At least one dose (LIK	"Pericarditis"	receiving both doses (US)	Modelna. 2.07 cases of myocarditisand 1.79 cases of percarditisper minion vaccinees
US	EEA) or 2 doses (US):			EEA
	schedule NR.	Risk interval: None applied (date of		Pfizer/BioNTech: 4.23 cases of myocarditis and 2.87 cases of pericarditis per million vaccinees
Lane 2021		vaccine launch to datalock point)		Moderna: 6.15 cases of myocarditis and 3.84 cases of pericarditis per million vaccinees
				US (after dose 2) Deizar (Piph) F 47 appender mugaer ditioned 2, 52 appender pariografitioner million vacainess
				Modema 3.65 cases of myocarditisand 2.69 cases of pericarditisper million vaccinees
VAERS* Jun 18a	Pfizer-BioNTech or	Mvocarditis	Crude rates per million	Events: 257 (92% within 5 d: 90% males)
	Moderna (but only 1 of	,	vaccinees	
Jan 1 to Jun 18 2021	257 cases since not	"Myocarditis," "pericarditis,"		Atleast Dose 1
l	approved for <18y at	"myopericarditis" or "chest pain" in the	Cases with an unknown	Males 12-15 yrs: 12.0 per million vaccinees
USA	that time)	symptom notes; "troponin" required	dose number were assigned	Males 16-1 / yrs: 8.2 per million vaccinees
Høed 2021	Schedule NP	element in the laboratory data.	to dose 1 or dose 2 in the	Females 12-15 yrs: 0 per million vaccinees
		CDC working case definition of probable	known doses: 15% occurred	
		myocarditis	following dose 1 and 85%	Males 12-15 yrs: 162.2 per million vaccinees
			occurred following dose 2	Males 16-17 yrs: 94.0 per million vaccinees
		Risk interval: Any timing	Ŭ	Females 12-15 yrs: 13.0 per million vaccinees
				Females 16-17 yrs: 13.4 per million vaccinees
VAERS* Jun 18b	AstraZeneca	Pericarditis	Crude rate per million	EEA
USA	Janssen	Ascertainment NR		AstraZeneca: 2.604 per million doses
	Moderna		Raw data available to	Janssen: 2.530 per million doses
Lazaros2021	Pfizer-BioNTech		calculate crude age and sex	Total vectored: 2.596 per million doses
			subgroup rates if needed.	Moderna: 4.023 per million doses
				Pfizer-BioNTech: 1.613 per million doses

Dataset Dates of data Country of Data	Vaccines Studied	Outcome(s); Case Ascertainment & Risk Interv al	Analysis	Results
	Dose and schedule not specified.			Total mRNA: 1.882 per million doses
CAEFISS & CVP	AstraZeneca, Modema (≥12 y), Pfizer-	Myocarditis or pericarditis	Reported rates per 100,000 doses administered	Events: 913
Up to Oct 8 2021	BioNTech (≥12 y)	Cases meeting Level 1-4 to Brighton Criteria of Diagnostic Certainty (not all		Moderna: 2.51 casesper 100,000 doses
Canada	Dose and schedule	probable or definitive)		Pfizer-BioNTech: 1.37 casesper 100,000 doses AstraZeneca: 0.72 casesper 100,000 doses
PHAC 2021	not specified.	Risk interval: Any timing		
Pellow Card Oct 13 Dec 9 2020 to Oct 13	AstraZeneca, Moderna, Pfizer- BioNTech	Myocarditis and pericarditis (including those from viral/other infective causes)	Reporting rates per million doses	<u>Overall</u> Pfizer-BioNTech: myocarditis 8 cases per million doses; pericarditis 6 cases per million doses Moderna: myocarditis 32 case per million doses; pericarditis 19 cases per million doses
2021	Afterdage 1 or 2:	Ascertainment NR		AstraZeneca: myocarditis 3 case per million doses; pericarditis 4 cases per million doses
UK	schedule NR	Risk interval: NR		Subgroups:
Medicines& Healthcare ProductsRegulatory				Myocarditis/pericarditis <18 yrs
Agency 2021				Pfizer-BioNTech: 10 cases per million doses
				AstraZeneca: 0 cases
				18-49 yrs Dfians Dia NTach, 18 coord, por million doord
				Moderna: 44 cases per million doses
				AstraZeneca: 8 cases per million doses
				≥50 yrs Pfizer-BioNTech: 5 cases per million doses
				Moderna: 29 casesper million doses
Israel MOH* May 30	Pfizer-BioNTech(≥16	Mvocarditis	Crude number of cases and	Dose 1:
Dec 2020 to May 30 2021	y)	Ascertainment NR	doses	27 cases of 5,401,150 vaccinated individuals (5 per million) (11 had pre-existing conditions)
	Dose 1 and 2;	Risk interval: 30 d after dose 2		Within 30 d after dose 2:
	schedule NR			121 cases of 5,049,424 vaccinated individuals (24 per million) (60 had pre-existing conditions)
EudraVigilanceOct 19**	AstraZeneca	Myocarditis, pericarditis	Crude number of case and	<u>Overall:</u>
Up to Oct 19 2021	Janssen Moderna	Ascertainment NR	doses	Moderna: 1578 cases of myocarditis and 850 cases of pericarditis across 61,172,753 doses administered + (25.8 per million & 13.9 per million)
EEA	Pfizer-BioNTech	Risk interval: NR		Pfizer: 3610 cases of myocarditis and 2883 cases of pericarditis across 424,162,518 doses administered† (8.5 per million & 6.8 per million)
European Medicines Agency 2021	Dose and schedule			AstraZeneca: 320 cases of myocarditis and 416 cases of pericarditis across 68,799,957 doses administered† (4.7 per million & 6.0 per million)
				Janssen: 103 cases of myocarditis and 101 cases of pericarditis across 15,782,596 doses administered (6.5 per million & 6.4 per million)
				Age<18y

Dataset	Vaccines Studied	Outcome(s); Case Ascertainment &	Analysis	Results
Country of Data		RISK INTERVAL		
				Moderna: 32 reports of myocarditis across 531,050 people receiving at least one dose† (60.3 events per million) Pfizer: 369 reports of myocarditis across 8,874,141 people receiving at least one dose† (41.6 events per million)

*Indicates passive surveillance system with mandatory/legal reporting requirements for healthcare providers of adverse events after COVID-19 vaccines.

†Number of administered vaccine doses from European Center for Disease Control (EDCD), up to end of Week 41 2021 (Oct 16 2021). Period of vaccine doses is shorter than event reporting to account for time period between receiving vaccine and experiencing the event of interest (i.e., individuals vaccinated on October 19 are unlikely to be reporting myocarditis as an AE on that same day)

 Table A3. Summary of risk of bias assessments for observational studies/surveillance data (question 1)

Dataset	Were the two groups similar and recruited from the same population?	Was vaccination status measured in a reliable or valid way?	Were confounding factors identified and appropriately addressed in design or analysis?	Were the outcomes measured in a valid and reliable way?	Was the follow up time long enough for outcomes to occur?	Were the large majority of cases likely to have been identified?	Overall assessment of risk of bias
Active Surveillance	Studies						
VSD Jun 26 Klein 2021 Ref ID 22	Y	Y	U	Y	Y	Y	Some concerns
Israel MOH May 31 Mevorach 2021 Ref ID 3440	Y	U	N	Y	Y	Y	Some concerns
Clalit Health May 24a Witberg Ref ID 3441	NA	Y	Y	Y	Y	Y	Low
Clalit Health May 24b Barda 2021 Ref ID 1282	Y	Y	Y	Y	Y	Y	Low
Israeli Defense Forces May 7 Levin 2021 Ref ID 512	NA	Y	N	Y	N	Y	Some concerns
Genesis Healthcare Feb 14 Bardenheier 2021a Ref ID 144	Y	Y	Y	Y	U	Y	Some concerns
Genesis Healthcare Jan 3 Bardenheier, 2021b ref ID 1972	Y	Y	Y	Y	U	Y	Some concerns
KPSC Jul 2 Simone 2021 Ref ID 22	Y	Y	U	Y	U	Y	Some concerns
Providence Health May 25 Diaz 2021 Ref ID 525	Y	Y	Ν	U	Ν	Y	High
VSD Oct 9 (Klein 2021 Oct ACIP)	Y	Y	U	Y	Y	Y	Some concerns
VSD Aug 21	ΙY	ΙΥ	ΙU	ΙY	ΙΥ	ΙY	Some concerns

Klein 2021 Aug							
ACIP)							
Passive Surveillance	e Studies	1	1			1	
VAERS Oct 6	NA	N	N	Y	Y	Ν	High
Su, 2021 (ACIP Oct							
20-21 2021 meeting)							
Rosenblum 2021	NA	N	N	U	U	N	High
VAFRS Jun 11	NA	N	N	U	Y	N	High
Gargano 2021				°	•		i iigi i
VAERS Aug 6	NA	Ν	Ν	Ν	U	Ν	High
Lane 2021							
VAERS Jun 18a	NA	Ν	Ν	U	U	Ν	High
Høeg 2021							
VAEPS lup 19b	ΝΛ		N			N	Lliah
		0		0	0	IN	i ligiti
Lazaros 2021							
CAEFISS & CVP	NA	U	Ν	Ν	Ν	U	High
PHAC 2021							-
Yellow Card Oct 13	NA	U	Ν	U	U	Ν	High
Medicines &							
Healthcare Products							
Regulatory Agency							
2021							
Israel MOH May 30	NA	U	Ν	U	Y	U	High
Israel Ministry of							
Health 2021		N N					L B le
Eudravigliance Oct	NA	Y	N	U	U	N	Hign
19 European Madiaisse							
Luropean iviedicines							
Agency 2021							

Table A4. Study characteristics of randomized controlled trials (question 1)

Trial name;	Eligibility,	Study	Arms	Baseline Demographics	Outcome(s);	Analysis	Results
Author (year);	Randomization &	Vaccine arm	Placebo arm		Safety Assessment		
Country (number of sites);	Blinding				-		
Dates of enrolment							
Funding							
Teen COVE trial,	Included adolescents	mRNA-1273 (Moderna),	Saline placebo	Total randomized: 3,732	Myocarditis&	Safety analysis	Myocarditis: 0
Phase 2/3,	12-17 у	2 doses 28 d apart	2 doses 28 d apart		pericarditis	includedall	Pericarditis: 0

Trial name;	Eligibility,	Study Arms		Baseline Demographics Outcome(s);		Analysis	Results
Author (vear):	Randomization &	Vaccine arm	Placebo arm		Safety Assessment	-	
Country (number of sites):	Blinding						
Dates of enrolment	5						
Funding							
		100 mcg per 0.5 ml dose	0.5 ml per dose	Total safety population		participantswho	
Ali (2021)	Exclusions travel		•••• ••• p ••• ••••	3 726	Solicited local and	received at least	
, (2021)	outside of USA 28 d	Randomized 2 489		0,120	systemic adverse	one injection	
LISA (26)	prior to screening:	Dose 1:2.486	Randomized: 1 2/3	Male 51%	reactions during 7 d	according to	
00A (20)	acute illness or fever	Dose 2:2.480	Dose 1:1 2/0	Mean age 14 3 v	after each injection:	treatment group	
Dec 0, 2020	24 h prior to or at	0030 2.2,400	$D_{0} = 2:1,220$	12 15 y: 74%		acauncingioup	
$E_{eb} 28 2020 =$	screening: previous	Safety population: 2,486	D09e 2. 1,222	16-17 v: 26%	ovents (AEs) defined		
1 60 20, 202 1	administration of an	Withdrawala:	Sofety population: 1.240	10-17 y. 2070	events (ALS), defined		
1184 (26)	invotigational SAPS	Afterdese 1:18	Salety population. 1,240	Wille 64 %	as any event hotor		
USA (20)		After dose 1.10	With drawala	Baseline SARS Call 2			
Inductor funded	Cov-2 vaccine;	Alterdose 2: 188	After dece 1: 6	Baseline SARS-Cov-2	exposure to study		
indusiry-iunded	pregnant or		After dose 1.0	Status.	vacciliation of any		
	breastieeding.		After dose 2:57	Positive: 216 (6%), similar	event already present		
	Demolerations d 0:4			Detween anns, $Missing (200, 700)$ sing the m			
	Randomized 2:1;			Missing: 268 (7%), similar	Intensity or frequency		
	centralized interactive			between anns	alter exposure,		
	response technology				observed of reported		
	system				during 28 d alter each		
	Study percented and				Injection;		
	Study personnel and				AEsteadingto		
	participantswere				discontinuation from a		
	blinded; pharmacists				dose and/or study		
	and vaccine				withdrawal, medically		
	administrators				attended (MAAEs) and		
	unblinded.				serious AE (SAEs),		
					throughout study period		
					l la blia de de sefetivale te		
					Unblinded salety data		
					independent data and		
					independent data and		
				T ()	safety monitoring board		
COVE trial,	Included adults≥18 y	mRNA-1273 (Moderna)	Saline placebo	Total randomized: 30,420	Solicited local and	Safety analysis	From associated
Phase 3	at appreciable risk of	2 doses 28 d apart	2 doses 28 d apart	Total safety population:	systemic adverse	Included all	publication:
	acquiring infection or	100 mcg per 0.5 mi dose	0.5 mi dose	30,351	reactions during 7 d	participantswno	
Baden (2021; primary	nigh risk of severe	Devidencies d. 45.040		Mala 50.00/	following each	received at least	Myocarditis: 0
	COVID-19, or both;	Randomized: 15,210	Dendemined 45 010	Male 52.6%	Injection;	one injection,	Pericarditis: 2 (68 d & 73
& EI-Santy (2021)	Evelueiane	Dose 1: 15, 181	Randomized: 15,210	Mean age 51.4 y	Unsolicited adverse	according to	d after dose 2) vaccine vs.
hul 07, 0000 , Oct 00, 0000	Exclusions:	Dose 2:14,711	Dose 1: 15,170	White 79.2%	events (AES) for 28 d	product received.	2 placebo
Jui 27, 2020 – OCt 23, 2020	immunosuppression	Cofetymenulation	DUSE 2: 14,017	10 to <05 y at fisk: 16.7%	inite stien in shuding		
	or received systemic	Safety population	Cofetymenylation	18 to <65 y not at risk:	Injection, including		
02A (88)	immunosuppressant/				(any event during a study		
In duration from dia d	Immune-moaitying	15,185	(Unsolicited AES):	≥05 y: 24.8%	(any event during study		
inaus(ry-tunaea	arugs for >14 a total	M646 days 12, 000 (15	15,100	Significant cardiac disease	not present before		
	In prior 6 mos; known	withdrawais: 233 (45		4.9%	exposure to injection or		
	nistory of SARS-CoV-	aiscontinued study due	withdrawais: 290 (69	HIV Infection 0.6%	any event already		
	2 Infection; pregnant	to SARS-CoV-2	aiscontinued study due	Develop 0AD0 0 M0	present that worsens		
	or breastfeeding,	diagnosis)	to SARS-CoV-2	Baseline SARS-CoV-2	atter exposure to study		
			diagnosis)	status:	vaccine;		

Trial name;	Eligibility,	Study Arms		Baseline Demographics	Outcome(s);	Analysis	Results	
Author (year);	Randomization &	Vaccine arm	Placebo arm	1	Safety Assessment	-		
Country (number of sites);	Blinding							
Dates of enrolment	Ŭ							
Funding								
	Randomized 1:1.			Positive: 680 (2.2%).	AEsleadingto			
	stratified by age (≥18			similar between arms:	discontinuation from a			
	$t_0 < 65 \text{ y ys} \ge 65 \text{ y}$			Missing: 523 (1 7%)	dose and/or study			
	and being at risk for			similar between arms	withdrawal MAAFs			
	severe Covid-19				and SAFs throughout			
	based on pre-existing				study period (1-759 d)			
	risk factors as per							
	CDC				MedDRA classification			
	centralized interactive				for all solicited adverse			
	response technology				reactionsand			
	system				unsolicited AFs			
	Study personnel and				Unblinded safety data			
	participantswere				reviewed by			
	blinded. but				independent data and			
	pharmacistsand				safety monitoring board			
	vaccine				g			
	administratorswere							
	unblinded;							
	participantsinformed							
	of group assignment							
	at end of blinded							
	phase and offered							
	vaccine.							
C4591001 Trial.	Included adolescents	BNT162b2 (Pfizer-	Saline placebo	Total randomized:	Solicited local and	12-15 y: Safety	Myocarditis/pericarditis: 0	
Phase 3 - adolescent cohort	12-15 y and adults	BioNTech)	2 doses 21 d apart	12-15 y: 2,264	systemic AEs during 7	analysisincluded	, ,	
	16-25 y who were	2 doses 21 d apart	0.3 ml perdose	16-25 y: 3,788	d following each	all participants who		
Frenck (2021)	healthy or with stable	30 mcg per 0.3 ml dose		, ,	injection;	received at least		
. ,	pre-existing			Total safety population:	Unsolicited AEs for 1	one injection.		
Oct 15, 2020 – Jan 12, 2021	conditions	Randomized:		12-15 y: 2,260	mo after dose 1 and			
				16-25 y: 1,098 (subset with	SAEs for 6 mosafter	16-25 y: subset of		
Argentina (NR), Brazil (NR),	Exclusions: medical	12-15 y: 1,134	Randomized:	e-diary data)	dose 2.	participantswho		
Germany (NR), South Africa	history of SARS-CoV-	Dose 1:1,131				received an e-diary		
(NR), Turkey (NR), USA (29)	2 infection or Covid-	Dose 2: 1,124	12-15 y: 1,130	Male 51%	MedDRA v23.1	to record		
	19 diagnosis;		Dose 1: 1,129	White 86%	classification.	reactogenicity		
Industry-funded	treatment with	16-25 y: 1,875	Dose 2:1,117			events		
	immunosuppressive	Dose 1: 1,869		Baseline SARS-CoV-2:	Unblinded safety data			
	therapy; diagnosed	Dose 2: 1,826	16-25 y: 1,913	Positive:	reviewed by			
	with		Dose 1: 1,906	12-15 y: 93 (4.1%), similar	independent data and			
	immunocompromising	Withdrawals:	Dose 2: 1,836	between arms	safety monitoring			
	condition			16-25 y: 64 (5.8%), similar	board; ongoing for 2 y			
		12-15 y	Withdrawals:	between arms	atter dose 2.			
	Randomized 1:1;	After dose 1:7						
	web-based system	Atter dose 2:0	12-15 y					
			After dose 1:12					
	Study personnel	16-25 y	Atter dose 2:1					
	evaluating safety	After dose 1:43	40.0-					
		Atter dose 2:20	16-25 y					

Trial name;	Eligibility,	Study Arms		Baseline Demographics	Outcome(s);	Analysis	Results
Author (year);	Randomization &	Vaccine arm	Placebo arm	1	Safety Assessment		
Country (number of sites);	Blinding				-		
Dates of enrolment							
Funding							
	were blinded to group		After dose 1:70				
	assignments		After dose 2:22				
C4591001 Trial, Phase 2/3	Included participants	BNT162b2 (Pfizer-	Saline placebo	Total randomized: 44,165	Solicited local and	Safety analysis	Myocarditis: 0
	≥16 y, healthy or with	BioNTech)	2 doses 21 d apart		systemic AEs during 7	includedall	
Polack(2021, primary	stable pre-existing	2 doses 21 d apart	0.3 ml dose	Total safety population:	d after each injection;	participantswho	
publication) & Thomas (2021)	conditions	30 mcg per 0.3 ml dose		43,847	Unsolicited AEs and	received at least	
		Devidencies d. 00.005	Developming d. 00,000	Mala 50.00/	SAEsfor 1 mo and 6	oneinjection	
hul 07, 0000 , Ostak sz00	Exclusions: medical	Randomized: 22,085	Randomized: 22,080	Male 50.9%	mos after dose 2,	for the spective of	
Jul 27, 2020 – October 29,	history of SARS-Cov-	Dose 1:22,030	Dose 1:22,030	Median age 51.0 y	respectively.	tonow-up time.	
2020	2 Infection of Covid-	D09e 2.21,759	Dose 2.21,030	>55 x 40 6%	ModDRA v23 1		
Argentina (1) Brazil (2)	treatment with	Safety population:	Safety population	White 82.0%	classification:		
Germany(6) South Africa (4)	immunosuppressive	21 926	21 921	Concestive heart failure	classification,		
Turkev (9) USA (130)	therapy diagnosed	21,020	21,021	0.5%	Unblinded safety data		
	with	Withdrawals:	Withdrawals:	Myocardial infarction 1 0%	reviewed by		
Industry-funded	immunocompromising	After dose 1:271	After dose 1: 380	Any malignancy 3.6%	independent data and		
,	condition	After dose 2: 167	After dose 2: 273	Rheumatic disease 0.3%	safety monitoring		
				AIDS/HIV 0.5%	board; ongoing for 2 y		
	Randomized 1:1;				after second dose.		
	web-based system			Baseline SARS-CoV-2			
				status:			
	Study personnel			Positive: 1,405 (3.2%),			
	evaluating safety			similar between arms			
	were blinded to group			Missing: 277 (0.6%),			
	assignments;			similar between arms			
	unblinded follow-up						
	Adulte >18 y boolthy	Ad26 COV/2 S (lancen)	Salina placoba	Total randomized: 11 325	Solicited local and	Safaty analysis	Boricarditis: 1 (<0, 1%)
ENSEMBLE IFIAI, Phase 3	or with stable pre-	1 dose	1 dose x 0 5ml	Total landomized. 44,325	systemic AEs 7 d after	included all	vaccine vs. 0 placebo
Sadoff (2021)	evisting conditions	5x10 ¹⁰ vp per 0.5 ml		Total safety population:	injection (for subset of	narticinantswho	
	excluded those who	dose		43.783	6.000 participants):	received injection	
Sep 21, 2020 - Jan 22, 2021	received		Randomized: 21.888		Unsolicited SAEs up		
, ,	chronic/recurrent	Randomized: 21,895	,	Male 54.9%	to 28 d after injection,		
Argentina, Brazil, Chile,	systemic		Safety population:	Median age 52 y	MAAEsuntil 6 mos		
Colombia, Mexico, Peru,	corticosteroids, or	Safety population:	21,888	White 58.7%	after vaccination, and		
South Africa, USA	antineoplastic and	21,895		Seriousheart condition	MAAEsleadingto		
	immunomodulating		Withdrawals: 96	2.3%	study withdrawal		
Industry-funded	agentsor	Withdrawals: 49		Immunocompromised from			
	radiotherapy in prior 6			plood transplant, immune	independent data and		
	mo before study			deficiencies, use of	satety monitoring board		
	study or are			immunoquercesing	cofoty data		
	suuy, or are			medicines 0.2%	Salety data.		
	piegnant			Immunocompromised from			
	Randomized 1.1			organ transplant <0 1%			
	stratified by site age						
	and being at risk for			Baseline SARS-CoV-2			
	severe Covid-19			status:			

Trial name;	Eligibility,	Study Arms		Baseline Demographics Outcome(s);		Analysis	Results
Author (vear):	Randomization &	Vaccine arm	Placebo arm		Safety Assessment	•	
Country (number of sites):	Blinding						
Dates of enrolment	5						
Funding							
·	based on pre-existing			Positive 4 217 (9 6%)			
	risk factors			similar between arms			
	interactive web			Missing: 1 271 (2 9%)			
	rosponso system			similar botwoon arms			
	Tesponse system			Sillinal Detweenanns			
	Dortinin onto and						
	study porconnol						
	(including LIC)						
	vaccine) binded until						
	entrerdiscontinuation						
	or an event			T ()			
AZD1222 Trial, Phase 3	Included adults≥18 y,	AZD1222 (AstraZeneca)	Saline placebo	l otal randomized: 32,451	Solicited local and	Safety analysis	Myocarditis/pericarditis: 0
E 1 (2004)	with stable pre-		2 doses 4 wks apart	-	systemic AEs 7 d after	Included all	
Falsey (2021)	existing conditions, at	5 x 10 ¹⁰ vp per dose		I otal safety population:	each injection;	participantswno	
	nign risk for exposure			32,379	Unsolicited AEs up to	received at least	
Aug 28, 2020 – Jan 15, 2021	to SARS-CoV-2 and	Randomized: 21,635			28 d after injection,	one injection.	
	at increased risk for	Dose 1:21,583	Randomized: 10,816	Male 55.6%	SAEs, MAAEs, and		
Chile, Peru, USA (88 total)	severe Covid-19	Dose 2:20,769	Dose 1:10,769	Mean age: 50.2 y	MEs of special interest		
			Dose 2:9951	≥18-64 y 77.6%	up to 730 d after		
Industry-funded	Exclusions: history of	Safety population:		≥65 y 22.4%	informed consent		
	SARS-CoV-2	21,587	Safety population:	White 79.0%			
	infection; confirmed		10,792	Seriousheart condition			
	or suspected	Withdrawals:		3.3%			
	immunodeficiency, or	After dose 1:283	Withdrawals:	Cancer 6.5%			
	with significant	After dose 2: 228	After dose 1:240	Immunocompromised due			
	disease; pregnant or		After dose 2:258	to solid organ			
	breastfeeding			transplantation < 0.1%			
				HIV infection 1.6%			
	Randomized 2:1,						
	stratified by age;			Baseline SARS-CoV-2			
	method NR			status:			
				Positive: 915 (2.8%),			
	Group assignment			similar between arms			
	unblinded for 7,635			Missing/not performed:			
	(35.3%)AstraZeneca			575 (1.8%), similar			
	and 4,157 (38.4%)			between arms			
	placebo participants,						
	after the second						
	dose.						
AZD1222	Adults≥18 y, healthy	AZD1222 (AstraZeneca)	Meningococcal ACWY	Total randomized: 24,422	Solicited local and	Safety analysis	Pericarditis: 1 vaccine (0
Phase 1/2/3, pooled analysis	or with stable pre-	2 doses 4-12 wks apart	vaccine (UK)		systemic AEs for 7 d	includedall	grade 3 severity) vs. 2 (1
	existing conditions, or	2.2-6.5x10 ¹⁰ vp per	OR	Total safety population:	after each injection	participantswho	grade 3 severity) controls
Voysey (2021a; primary	at risk of exposure	0.5ml dose, 2	Meningococcal ACWY	24,244	observed by	received at least	
publication) & Voysey (2021b)	(health and social		vaccine (dose 1) + saline		investigatororreported	one injection.	
	care setting workers,		placebo (dose 2; Brazil)	Male 44%	by participant;		
	58.5%)		OR	Median age NR			
Apr 23, 2020 – Dec 6, 2020		Randomized: 12,408		18-55 y 82.5%			

Trial name;	Eligibility,	Study Arms		Baseline Demographics	Outcome(s);	Analysis	Results
Author (year);	Randomization &	Vaccine arm	Placebo arm		Safety Assessment		
Country (number of sites);	Blinding						
Dates of enrolment							
Funding							
	Exclusions: confirmed		Saline placebo (South	56-69 y 11.3%	Unsolicited AEs		
Brazil (6), South Africa (8), UK	or suspected		Africa)	70+y6.1%	through to 28 d after		
(5+19)	immunosuppressive	Safety population:		White 75.2%	each injection, and		
	or immunodeficiency	12,282 (after exclusion	For all: 2 doses 4-12	Cardiovascular disorder	SAEs and AEsof		
Industry-funded	state; current	of 52 participants in HIV	wks apart	(includescardiac	special interest		
	diagnosis of cancer;	cohort)	0.5 ml dose	diseases) 12.3%	throughout study period		
	pregnantor				from last dose to 364 d.		
	breastfeeding	WithdrawalsNR	Randomized: 12014	Baseline SARS-CoV-2			
				status:	MedDRA v23.1		
	Randomized1:1,		Safety population:	Positive: 731 (3.0%),	classification, severity		
	stratified by study site		11,962 (after exclusion	similar between arms	classified according to		
	and study group;		of 52 participants in HIV	Missing: 200 (0.8%),	FDA toxicity rating		
	secure web platform		cohort)	similar between arms	scales.		
	Single blind (Brazil,		WithdrawalsNR	Sensitivity analyses for	Independent data		
	UK); double blind			participants positive for	monitoring safety board		
	(South Africa) - study			SARS-Cov-2 at baseline	reviewed safety data		
	personnel and			and using ITT were similar	on an ongoing basis		
	participantsblinded,			to main results			
	butpharmacist						
	preparing vaccines						
	unblinded						

AE: adverse event(s); LTFU: lost to follow-up; MAAE: medically-attended adverse event(s); mcg: microgram(s); mo: month(s); no.: number; NR: not reported; SAE: serious adverse event(s); vp: viral particle(s); wks: weeks; y: year(s)

Table A5. Risk of bias assessments for randomized controlled trials (question 1)

Vaccine (Trial name)	Randomization	Deviations from intended	Missing	Measurement	Selection	Overall assessment of
		interventions	outcome data	or the outcome	reported result	TISK OF DIAS
Moderna (Teen COVE Trial)	Low	Low	Some concerns	Low	Low	Some concerns
Ali 2021						
Moderna (COVE Trial)	Low	Low	Low	Low	Low	Low
Baden 2021 & El-Sahly 2021						
Pfizer-BioNTech (Teen C4591001 Trial)	Low	Low	Low	Some concerns	Low	Some concerns
Frenck 2021						
Pfizer-BioNTech (C4591001 Trial)	Low	Low	Low	Some concerns	Low	Some concerns
Polack 2021 & Thomas 2021						
AstraZeneca (AZD1222 Trial)	Low	Some concerns	Some concerns	Low	Low	Some concerns
Falsey 2021						
AstraZeneca (Oxford Vaccine Trial)	Low	Some concerns	Some concerns	Low	Low	Some concerns
Voysey 2021a & 2021b						
Janssen (ENSEMBLE Trial)	Low	Low	Low	Low	Low	Low
Sadoff 2021						

Mycarditis Very low Moderna (28 d) Arderna (28 d) 3.726 O RCTs provided very uncertain evidence about the incidence of mycoarditis after receipt of Moderna in youth 12-17 years of age. Very low ^a Adolescents and young adults 12-25 y USA (29) Pfizer (21 d) 3.367 0 (assumed, NR) RCTs provided very uncertain evidence about the incidence of mycoarditis after receipt of Moderna in young adults. Very low ^a Adolescents and adults 216 y Argentina (1). Brazi (2). Germany (6), South Africa (4), Turkey (9), USA Pfizer (21 d) 43,847 0 RCTs provided very uncertain evidence about the incidence of mycoarditis after receipt of Pfizer in adolescents and young adults. Very low ^b Adults 218 y, at risk of exposure to SARS-CoV-2 and/or increased risk for severe posure to SARS-CoV-2 and increased risk for severe evere CoV-19 Moderna (28 d) 218 y, at high-risk of exposure to SARS-CoV-2 and increased risk for severe posure to SARS-CoV-2 and increased risk for severe posure to SARS-CoV-2 and increased risk for severe severe CoV-19 AstraZeneca (28 d) 32.379 0 (assumed, NR) 218 y, at high-risk of exposure to SARS-CoV-2 and increased risk for severe posure to SARS-CoV-2 and increased risk for severe Souri 19 Brazi (6).South Arrica (8). UK (24) AstraZeneca (4- 24.244 24.244 0 (assumed, NR) 218 y Sth risk of exposure to S	Age category	Age, risk status	Country (number of sites)	Vaccine (risk interval)	Number of participants in safety analysis	Number of participants with outcome	Conclusion	GRADE
12-17 y 12-17 y USA (26) Moderna (28 d) 3,726 0 RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of Moderna in yours and young adults Very low* Adolescents and young adults 12-25 y USA (29) Pfizer (21 d) 3,357 0 (assumed, NR) RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of Moderna in yours adults. Very low* Adolescents and adults 216 y Argentina (1), Brazil (2), Germany (6), South Artrica (4), Trakey (9), USA (130) Pfizer (21 d) 43,847 0 RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of Pfizer in adolescents and young adults. Very low* Adults 216 y Argentina (1), Brazil (2), Germany (6), South Artrica (4), Trakey (9), USA (130) Pfizer (21 d) 43,847 0 RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of Pfizer in adolescents and adults. Very low* Adults 218 y, at risk of exposure to SARS-CoV-2 and/or increased risk for severe Covid-19 Moderna (28 d) 30.351 0 RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of Pfizer in adolescents and adults. Very low* 218 y, stiph-risk of exposure to SARS-CoV-2 Ofile, Peru, USA (29) AstraZeneca (28 d) 32,379 0 (assumed, NR)		Myocarditis						
Adolescents and young adults 12-25 y USA (29) Pfizer (21 d) 3.357 0 (assumed, NR) RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of nor myocarditis after receipt of covid-19 Very low* Adults ≥18 y, afrisk of exposure to SARS-CoV-2 and/or increased risk for severe Covid-19 Chile, Peru, USA (28) 30.351 0 Cassumed, NR) RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of currently available vaccine by adults. Very low* Adults ≥18 y, afrisk of exposure to SARS-CoV-2 Chile, Peru, USA (28) AstraZeneca (28) 32.379 0 (assumed, NR) Prizer (21 d) Very low* 18 y, 59% at risk of exposure to SARS-CoV-2 Palsey Fasey AstraZeneca (4: 12 w k) 24.244 0 (assumed, NR) eutits eutits eutits 18 y, 59% at risk of exposure to SARS-CoV-2 Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa (8), USA (number of sites NR) Janssen (single dose)	12-17 y	12-17 y	USA (26) Ali	Moderna (28 d)	3,726	0	RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of Moderna in youth 12-17 years of age.	Very low ^a
Adolescents and adults 216 y Argentina (1), South Africa (4), Turkey (9), USA Pfizer (21 d) 43,847 0 RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of Pfizer in adolescents and adults. Very low ⁵ Adults 218 y, at risk of exposure to SARS-CoV-2 and/or increased risk for severe Covid-19 USA (99) Moderna (28 d) 30,351 0 RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of corrents and adults. Very low ⁵ 218 y, at risk of exposure to SARS-CoV-2 and increased risk for severe Covid-19 Chile, Peru, USA (88 altogether) AstraZeneca (28 d) 32,379 0 (assumed, NR) Plassumed, NR) Very low ⁵ 218 y, at high-risk of exposure to SARS-CoV-2 and increased risk for severe Covid-19 Brazil (6), South Africa (8), UK (24) AstraZeneca (24 12 wk) 32,379 0 (assumed, NR) Plassumed, NR) 218 y, 59% at risk of exposure to SARS-CoV-2 and increased risk for severe Covid-19 Brazil (6), South Africa (8), UK (24) AstraZeneca (4- 12 wk) 24,244 0 (assumed, NR) Plassumed, NR)	Adolescents and young adults	12-25 y	USA (29) Frenck	Pfizer (21 d)	3,357	0 (assumed, NR)	RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of Pfizer in adolescents and young adults.	Very low ^a
Adults ≥18 y, at risk of exposure to SARS-CoV-2 and/or located risk for severe Covid-19 USA (99) Moderna (28 d) 30,351 0 RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of currently available vaccine by adults Very low b ≥18 y, at high-risk of exposure to SARS-CoV-2 and increased risk for severe Covid-19 Chile, Peru, USA (88 altogether) AstraZeneca (28 d) 32,379 0 (assumed, NR) Proceeding the receipt of currently available vaccine by adults ≥18 y, 59% at risk of exposure to SARS-CoV-2 Brazil (6), South Africa (8), UK (24) AstraZeneca (4- 12 w k) 24,244 0 (assumed, NR) ≥18 y Solve to SARS-CoV-2 Brazil (6), South Africa, USA (10 where of sites NR) Janssen (single dose) 43,783 0 (assumed, NR) ≥18 y Argentina, Brazil, Onlie, Colombia, Mexico, Peru, South Africa, USA (number of sites NR) Janssen (single dose) 43,783 0 (assumed, NR) ≥18 y Sadoff Sadoff Sadoff Sadoff Sadoff Sadoff Sadoff	Adolescents and adults	≥16 y	Argentina (1), Brazil (2), Germany (6), South Africa (4), Turkey (9), USA (130) Polack/Thomas	Pfizer (21 d)	43,847	0	RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of Pfizer in adolescents and adults.	Very low [▷]
≥18 y, at high-risk of exposure to SARS-CoV-2 and increased risk for severe Covid-19 Chile, Peru, USA (88 altogether) AstraZeneca (28 d) 32,379 0 (assumed, NR) ≥18 y, 59% at risk of exposure to SARS-CoV-2 Brazil (6), South Africa (8), UK (24) AstraZeneca (4- 12 w k) 24,244 0 (assumed, NR) ≥18 y Voysey Janssen (single dose) 43,783 0 (assumed, NR) ≥18 y Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, USA (number of sites NR) Janssen (single dose) 43,783 0 (assumed, NR) Pericarditis Sadoff Image: Colombia dose Sadoff Image: Colombia dose Image: Colombia dose	Adults	≥18 y, at risk of exposure to SARS-CoV-2 and/or increased risk for severe Covid-19	USA (99) Baden/⊟-Sahly	Moderna (28 d)	30,351	0	RCTs provided very uncertain evidence about the incidence of myocarditis after receipt of currently available vaccine by adults	Very low ^b
≥18 y, 59% at risk of exposure to SARS-CoV-2 Brazil (6), South Africa (8), UK (24) AstraZeneca (4- 12 w k) 24,244 0 (assumed, NR) Voysey Voysey Janssen (single dose) 43,783 0 (assumed, NR) ≥18 y Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, USA (number of sites NR) Janssen (single dose) 43,783 0 (assumed, NR) Pericarditis Pericarditis Voysey 43,783 0 (assumed, NR)		≥18 y, at high-risk of exposure to SARS-CoV-2 and increased risk for severe Covid-19	Chile, Peru, USA (88 altogether) Falsey	AstraZeneca (28 d)	32,379	0 (assumed, NR)		
 ≥18 y Àrgentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, USA (number of sites NR) Banssen (single dose) 43,783 0 (assumed, NR) 0 (assumed, NR) 		≥18 y, 59% at risk of exposure to SARS-CoV-2	Brazil (6), South Africa (8), UK (24) Voysey	AstraZeneca (4- 12 w k)	24,244	0 (assumed, NR)		
Pericarditis		≥18 y	Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, USA (number of sites NR)	Janssen (single dose)	43,783	0 (assumed, NR)		
		Pericarditis	Sauuri					

Appendix 4. Summary of Findings from the Randomized Controlled Trials (question 1)

Age category	Age, risk status	Country (number of sites)	Vaccine (risk interval)	Number of participants in safety analysis	Number of participants with outcome	Conclusion	GRADE
12-17 y	12-17 y	USA (26) Ali	Moderna (28 d)	3,726	0	RCTs provided very uncertain evidence about the incidence of pericarditis after receipt of Moderna in youth 12-17 years f age.	Very low ^a
Adolescents and young adults	12-25 y	USA (29) Frenck	Pfizer (21 d)	3,357	0 (assumed, NR)	RCTs provided very uncertain evidence about the incidence of pericarditis after receipt of Pfizer in adolescents and young adults.	Very low ^a
Adolescents and adults	≥16 y	Argentina (1), Brazil (2), Germany (6), South Africa (4), Turkey (9), USA (130) Polack/Thomas	Pfizer (21 d)	43,847	0 (assumed, NR)	RCTs provided very uncertain evidence about the incidence of pericarditis after receipt of Pfizer in adolescents and adults.	Very low ^b
Adults	≥18 y, at risk of exposure to SARS-CoV-2 and/or increased risk for severe Covid-19	USA (99) Baden/⊟-Sahly	Moderna (28 d)	30,351	2 (68 d & 73 d post-second dose) vs. 2 placebo	RCTs provided very uncertain evidence about the incidence of pericarditis after receipt of currently available vaccine by	Very low ^b
	≥18 y, at high-risk of exposure to SARS-CoV-2 and increased risk for severe Covid-19	Chile, Peru, USA (88 altogether) Falsey	AstraZeneca (28 d)	32,379	0 (assumed, NR)	currently available vaccine by adults	
	≥18 y, 59% at risk of exposure to SARS-CoV-2	Brazil (6), South Africa (8), UK (24)	AstraZeneca (4- 12 w k)	24,244	1 vs. 2 controls		
	≥18 y	Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa, USA (number of sites NR) Sadoff	Janssen (single dose)	43,783	1 (<0.1%) vs. 0 placebo		

GRADE Explanations:

^a Rated down for indirectness since results by sex are expected to differ; rated down twice for high imprecision for these very rare events.

^b Rated down twice for indirectness and for imprecision for these very rare events.